JP4863876B2 - A2bアデノシン受容体アンタゴニスト - Google Patents
A2bアデノシン受容体アンタゴニスト Download PDFInfo
- Publication number
- JP4863876B2 JP4863876B2 JP2006538172A JP2006538172A JP4863876B2 JP 4863876 B2 JP4863876 B2 JP 4863876B2 JP 2006538172 A JP2006538172 A JP 2006538172A JP 2006538172 A JP2006538172 A JP 2006538172A JP 4863876 B2 JP4863876 B2 JP 4863876B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- dione
- dihydropyrimidine
- compound
- nitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940121359 adenosine receptor antagonist Drugs 0.000 title abstract description 6
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title abstract description 6
- 101150078577 Adora2b gene Proteins 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 157
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 76
- 239000001257 hydrogen Substances 0.000 claims abstract description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 34
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims abstract description 15
- 208000019693 Lung disease Diseases 0.000 claims abstract description 10
- 208000006673 asthma Diseases 0.000 claims abstract description 10
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 8
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 7
- 208000026278 immune system disease Diseases 0.000 claims abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 5
- 230000033115 angiogenesis Effects 0.000 claims abstract description 5
- 206010014561 Emphysema Diseases 0.000 claims abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract 4
- 206010035664 Pneumonia Diseases 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 125000001424 substituent group Chemical group 0.000 claims description 57
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 19
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 17
- 229960005305 adenosine Drugs 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Chemical group 0.000 claims description 6
- 239000011593 sulfur Chemical group 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical group C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- -1 n-decyl Chemical group 0.000 description 88
- 238000000034 method Methods 0.000 description 55
- 239000000203 mixture Substances 0.000 description 46
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 45
- 125000006494 2-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 44
- 125000003118 aryl group Chemical group 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 35
- 125000003545 alkoxy group Chemical group 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 229910052736 halogen Inorganic materials 0.000 description 23
- 150000002367 halogens Chemical class 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 22
- 125000004181 carboxyalkyl group Chemical group 0.000 description 22
- 125000004093 cyano group Chemical group *C#N 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- 108050000203 Adenosine receptors Proteins 0.000 description 19
- 102000009346 Adenosine receptors Human genes 0.000 description 19
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 125000000623 heterocyclic group Chemical group 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 125000000392 cycloalkenyl group Chemical group 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 125000002947 alkylene group Chemical group 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 12
- WRWQSJUSHNWSNL-UHFFFAOYSA-N 6-methyl-5-nitro-1,3-dipropylpyrimidine-2,4-dione Chemical compound CCCN1C(C)=C([N+]([O-])=O)C(=O)N(CCC)C1=O WRWQSJUSHNWSNL-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 229930194542 Keto Natural products 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 125000004423 acyloxy group Chemical group 0.000 description 9
- 125000005110 aryl thio group Chemical group 0.000 description 9
- 125000004104 aryloxy group Chemical group 0.000 description 9
- 125000005553 heteroaryloxy group Chemical group 0.000 description 9
- 125000000468 ketone group Chemical group 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- ZTGWXXOUUKHQLW-UHFFFAOYSA-N 1-nitropyrimidine-2,4-dione Chemical compound [O-][N+](=O)N1C=CC(=O)NC1=O ZTGWXXOUUKHQLW-UHFFFAOYSA-N 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 8
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 8
- 150000001540 azides Chemical class 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 125000005368 heteroarylthio group Chemical group 0.000 description 8
- 125000004470 heterocyclooxy group Chemical group 0.000 description 8
- 125000004468 heterocyclylthio group Chemical group 0.000 description 8
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 125000003367 polycyclic group Chemical group 0.000 description 7
- ZJONPIRNUOSPQW-UHFFFAOYSA-N 1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carbaldehyde Chemical compound FC(F)(F)C1=CC=CC(CN2N=CC(C=O)=C2)=C1 ZJONPIRNUOSPQW-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000033 alkoxyamino group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229930195734 saturated hydrocarbon Natural products 0.000 description 5
- 125000005017 substituted alkenyl group Chemical group 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- PXCDSZCZMQXGLT-UHFFFAOYSA-N 1-[[4-(trifluoromethyl)phenyl]methyl]-5H-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1C(=O)NC(=O)C2=C1C=CN2 PXCDSZCZMQXGLT-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IVDXTRMSPBIIFM-UHFFFAOYSA-N 5-nitro-1-[[4-(trifluoromethyl)phenyl]methyl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C([N+](=O)[O-])=CN1CC1=CC=C(C(F)(F)F)C=C1 IVDXTRMSPBIIFM-UHFFFAOYSA-N 0.000 description 4
- BBFJPUDLETXJCY-UHFFFAOYSA-N 6-methyl-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(C)NC1=O BBFJPUDLETXJCY-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000001593 cAMP accumulation Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- WOXHPHOZJMLUFE-UHFFFAOYSA-N 1-benzylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C=NN1CC1=CC=CC=C1 WOXHPHOZJMLUFE-UHFFFAOYSA-N 0.000 description 3
- OWAHOYKKKIEKPM-UHFFFAOYSA-N 1-ethyl-6-methyl-5-nitro-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C([N+]([O-])=O)=C(C)N(CC)C1=O OWAHOYKKKIEKPM-UHFFFAOYSA-N 0.000 description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- CVTDHCYRKGQTOT-UHFFFAOYSA-N 6-methyl-1,3-dipropylpyrimidine-2,4-dione Chemical compound CCCN1C(C)=CC(=O)N(CCC)C1=O CVTDHCYRKGQTOT-UHFFFAOYSA-N 0.000 description 3
- CZRQKJMIOGNEIQ-UHFFFAOYSA-N 6-methyl-5-nitro-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)NC(C)=C([N+]([O-])=O)C1=O CZRQKJMIOGNEIQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 150000007942 carboxylates Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- CUTDJCLKKQWXGM-UHFFFAOYSA-N ethyl 1-benzylpyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC=C1 CUTDJCLKKQWXGM-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 125000005549 heteroarylene group Chemical group 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HJPOQNKXQHXEKE-UHFFFAOYSA-N (1-benzylpyrazol-4-yl)methanol Chemical compound C1=C(CO)C=NN1CC1=CC=CC=C1 HJPOQNKXQHXEKE-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- BXIGAOOEYIYEFN-UHFFFAOYSA-N 3-ethyl-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound CCN1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O BXIGAOOEYIYEFN-UHFFFAOYSA-N 0.000 description 2
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 2
- JGXZJIYPZVRXNP-ZHACJKMWSA-N 6-[(e)-2-(1-benzylpyrazol-4-yl)ethenyl]-5-nitro-1,3-dipropylpyrimidine-2,4-dione Chemical compound O=C1N(CCC)C(=O)N(CCC)C(\C=C\C2=CN(CC=3C=CC=CC=3)N=C2)=C1[N+]([O-])=O JGXZJIYPZVRXNP-ZHACJKMWSA-N 0.000 description 2
- QXTPKWUMRQWSKN-UHFFFAOYSA-N 6-methyl-1,3-bis(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CC(C)CN1C(C)=C([N+]([O-])=O)C(=O)N(CC(C)C)C1=O QXTPKWUMRQWSKN-UHFFFAOYSA-N 0.000 description 2
- FNIKOGLKWWBYHD-UHFFFAOYSA-N 6-methyl-1-(2-methylpropyl)-5-nitro-3-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(C)=C([N+]([O-])=O)C(=O)N1CCC1=CC=CC=C1 FNIKOGLKWWBYHD-UHFFFAOYSA-N 0.000 description 2
- SHVCSCWHWMSGTE-UHFFFAOYSA-N 6-methyluracil Chemical compound CC1=CC(=O)NC(=O)N1 SHVCSCWHWMSGTE-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- MVOLUQHIASOMOM-UHFFFAOYSA-N [1-[(4-methylphenyl)methyl]pyrazol-4-yl]methanol Chemical compound C1=CC(C)=CC=C1CN1N=CC(CO)=C1 MVOLUQHIASOMOM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000005156 substituted alkylene group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- QSXREDPBMQKKAY-UHFFFAOYSA-N (1-methylpyrazol-4-yl)methanol Chemical compound CN1C=C(CO)C=N1 QSXREDPBMQKKAY-UHFFFAOYSA-N 0.000 description 1
- UCPVQFRIXFGLOJ-UHFFFAOYSA-N (1-phenylpyrazol-4-yl)methanol Chemical compound C1=C(CO)C=NN1C1=CC=CC=C1 UCPVQFRIXFGLOJ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KTKDYVVUGTXLJK-UHFFFAOYSA-N 1,1-dipropylurea Chemical compound CCCN(C(N)=O)CCC KTKDYVVUGTXLJK-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- OSTDULKDQDIIKB-UHFFFAOYSA-N 1,3,6-trimethyl-5-nitropyrimidine-2,4-dione Chemical compound CC1=C([N+]([O-])=O)C(=O)N(C)C(=O)N1C OSTDULKDQDIIKB-UHFFFAOYSA-N 0.000 description 1
- GRDXZRWCQWDLPG-UHFFFAOYSA-N 1,3,6-trimethylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)N(C)C(=O)N1C GRDXZRWCQWDLPG-UHFFFAOYSA-N 0.000 description 1
- GUBGKLYUXWCFEA-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound O=C1N(CCOC)C(=O)N(CCOC)C(C2=CN(N=C2)C=2C=CC=CC=2)=C1[N+]([O-])=O GUBGKLYUXWCFEA-UHFFFAOYSA-N 0.000 description 1
- RFGJNFGWCQGRTM-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CCOC)C(=O)N(CCOC)C(C2=CN(C)N=C2)=C1[N+]([O-])=O RFGJNFGWCQGRTM-UHFFFAOYSA-N 0.000 description 1
- RLQGDWKIGLELBX-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCOC)C(=O)N(CCOC)C=2C=C1C=1C=NN(C)C=1 RLQGDWKIGLELBX-UHFFFAOYSA-N 0.000 description 1
- JATJGXXVCMFHJZ-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCOC)C(=O)N(CCOC)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 JATJGXXVCMFHJZ-UHFFFAOYSA-N 0.000 description 1
- IKOHXEGDOSIHSW-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound COCCN1C(C)=C([N+]([O-])=O)C(=O)N(CCOC)C1=O IKOHXEGDOSIHSW-UHFFFAOYSA-N 0.000 description 1
- NWZHMVZQTCBMTB-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-6-methylpyrimidine-2,4-dione Chemical compound COCCN1C(C)=CC(=O)N(CCOC)C1=O NWZHMVZQTCBMTB-UHFFFAOYSA-N 0.000 description 1
- IMONJUZDBZQTFM-UHFFFAOYSA-N 1,3-bis(2-methylpropyl)-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CC(C)C)C(C2=CN(N=C2)C=2C=CC=CC=2)=C1[N+]([O-])=O IMONJUZDBZQTFM-UHFFFAOYSA-N 0.000 description 1
- FKSAQKOKBWGJLU-UHFFFAOYSA-N 1,3-bis(2-methylpropyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CC(C)C)C(C2=CN(C)N=C2)=C1[N+]([O-])=O FKSAQKOKBWGJLU-UHFFFAOYSA-N 0.000 description 1
- YPJYCXBZLFQBTL-UHFFFAOYSA-N 1,3-bis(2-methylpropyl)-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CC(C)C)C=2C=C1C=1C=NN(C)C=1 YPJYCXBZLFQBTL-UHFFFAOYSA-N 0.000 description 1
- ZRLQEWOWUISZKG-UHFFFAOYSA-N 1,3-bis(2-methylpropyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CC(C)C)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 ZRLQEWOWUISZKG-UHFFFAOYSA-N 0.000 description 1
- GXPHKVNBRUBEAW-UHFFFAOYSA-N 1,3-bis(2-phenylethyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(N=C3)C=3C=CC=CC=3)NC=2C(=O)N(CCC=2C=CC=CC=2)C(=O)N1CCC1=CC=CC=C1 GXPHKVNBRUBEAW-UHFFFAOYSA-N 0.000 description 1
- XESHIBPLKAVKPM-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C1=COC=C1CN1C(=O)N(CC2=COC=C2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1C1=CC=CC=C1 XESHIBPLKAVKPM-UHFFFAOYSA-N 0.000 description 1
- BAIYZJVFQVIJBI-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)CC2=COC=C2)=C([N+]([O-])=O)C(=O)N1CC1=COC=C1 BAIYZJVFQVIJBI-UHFFFAOYSA-N 0.000 description 1
- ZXIWHLQPFDBWGC-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N1)=CC2=C1C(=O)N(CC1=COC=C1)C(=O)N2CC1=COC=C1 ZXIWHLQPFDBWGC-UHFFFAOYSA-N 0.000 description 1
- WIUBCUMORJHAOF-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(N=C3)C=3C=CC=CC=3)NC=2C(=O)N(CC2=COC=C2)C(=O)N1CC=1C=COC=1 WIUBCUMORJHAOF-UHFFFAOYSA-N 0.000 description 1
- VZCUIIVGPFMKTR-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC2=COC=C2)C(C)=C([N+]([O-])=O)C(=O)N1CC=1C=COC=1 VZCUIIVGPFMKTR-UHFFFAOYSA-N 0.000 description 1
- IGBXFKSOOYXPDT-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-6-methylpyrimidine-2,4-dione Chemical compound O=C1N(CC2=COC=C2)C(C)=CC(=O)N1CC=1C=COC=1 IGBXFKSOOYXPDT-UHFFFAOYSA-N 0.000 description 1
- FAVXHODBYJJUTB-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(C=2C=CC=CC=2)N=C1 FAVXHODBYJJUTB-UHFFFAOYSA-N 0.000 description 1
- VYYOIZHXYZPJBS-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(C)N=C1 VYYOIZHXYZPJBS-UHFFFAOYSA-N 0.000 description 1
- MJQBOIMTWXGPLG-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C2=C1C=C(C1=CN(C)N=C1)N2 MJQBOIMTWXGPLG-UHFFFAOYSA-N 0.000 description 1
- KQNNTWOJNBWUNG-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C2=C1C=C(C1=CN(N=C1)C=1C=CC=CC=1)N2 KQNNTWOJNBWUNG-UHFFFAOYSA-N 0.000 description 1
- QQXQPOMHCZPKFR-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C([N+]([O-])=O)=C1C QQXQPOMHCZPKFR-UHFFFAOYSA-N 0.000 description 1
- FAIVXHBWPVXWAW-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-6-methylpyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C=C1C FAIVXHBWPVXWAW-UHFFFAOYSA-N 0.000 description 1
- FVKBVEXRIGSLAW-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C=1C=CC=CC=1C(F)N1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1C1=CC=CC=C1 FVKBVEXRIGSLAW-UHFFFAOYSA-N 0.000 description 1
- ORKRTXKUSDMMPU-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)C(F)C=2C=CC=CC=2)=C([N+]([O-])=O)C(=O)N1C(F)C1=CC=CC=C1 ORKRTXKUSDMMPU-UHFFFAOYSA-N 0.000 description 1
- BJTNVQFANNBECU-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N1)=CC2=C1C(=O)N(C(F)C=1C=CC=CC=1)C(=O)N2C(F)C1=CC=CC=C1 BJTNVQFANNBECU-UHFFFAOYSA-N 0.000 description 1
- MHPIKQMBECHZLE-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(N=C3)C=3C=CC=CC=3)NC=2C(=O)N(C(F)C=2C=CC=CC=2)C(=O)N1C(F)C1=CC=CC=C1 MHPIKQMBECHZLE-UHFFFAOYSA-N 0.000 description 1
- RWIJTVGRJAASKX-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitropyrimidine-2,4-dione Chemical compound C=1C=CC=CC=1C(F)N1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F RWIJTVGRJAASKX-UHFFFAOYSA-N 0.000 description 1
- PUTBUVMEDUJKGN-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(CC=4C(=CC=CC=4)F)N=C3)NC=2C(=O)N(C(F)C=2C=CC=CC=2)C(=O)N1C(F)C1=CC=CC=C1 PUTBUVMEDUJKGN-UHFFFAOYSA-N 0.000 description 1
- GJVPZLCBQJUGIN-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(C(F)C=2C=CC=CC=2)C(C)=C([N+]([O-])=O)C(=O)N1C(F)C1=CC=CC=C1 GJVPZLCBQJUGIN-UHFFFAOYSA-N 0.000 description 1
- VEPRCCJEIDFZPZ-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-methylpyrimidine-2,4-dione Chemical compound O=C1N(C(F)C=2C=CC=CC=2)C(C)=CC(=O)N1C(F)C1=CC=CC=C1 VEPRCCJEIDFZPZ-UHFFFAOYSA-N 0.000 description 1
- GKDWQQINCAEWIX-UHFFFAOYSA-N 1,3-di(cyclobutyl)-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C1CCC1N1C(=O)N(C2CCC2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1C1=CC=CC=C1 GKDWQQINCAEWIX-UHFFFAOYSA-N 0.000 description 1
- AOYGVBJPRLEXLN-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)C2CCC2)=C([N+]([O-])=O)C(=O)N1C1CCC1 AOYGVBJPRLEXLN-UHFFFAOYSA-N 0.000 description 1
- GIRFWJPOIWUFGI-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N1)=CC2=C1C(=O)N(C1CCC1)C(=O)N2C1CCC1 GIRFWJPOIWUFGI-UHFFFAOYSA-N 0.000 description 1
- VSOVLMJBKMFSLN-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(N=C3)C=3C=CC=CC=3)NC=2C(=O)N(C2CCC2)C(=O)N1C1CCC1 VSOVLMJBKMFSLN-UHFFFAOYSA-N 0.000 description 1
- ISLUTRJFNXCLEM-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitropyrimidine-2,4-dione Chemical compound C1CCC1N1C(=O)N(C2CCC2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F ISLUTRJFNXCLEM-UHFFFAOYSA-N 0.000 description 1
- DWZCTKLYIZZZAN-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(C4CCC4)C(=O)N(C4CCC4)C=3C=2)=C1 DWZCTKLYIZZZAN-UHFFFAOYSA-N 0.000 description 1
- JKVRFTLOCLVZIL-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(C2CCC2)C(C)=C([N+]([O-])=O)C(=O)N1C1CCC1 JKVRFTLOCLVZIL-UHFFFAOYSA-N 0.000 description 1
- GNJVRMFBYCSMTF-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-methylpyrimidine-2,4-dione Chemical compound O=C1N(C2CCC2)C(C)=CC(=O)N1C1CCC1 GNJVRMFBYCSMTF-UHFFFAOYSA-N 0.000 description 1
- RWOQWLVTLIYOFH-UHFFFAOYSA-N 1,3-dibutyl-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C(C2=CN(N=C2)C=2C=CC=CC=2)=C1[N+]([O-])=O RWOQWLVTLIYOFH-UHFFFAOYSA-N 0.000 description 1
- NEOPMLYYUWCGAK-UHFFFAOYSA-N 1,3-dibutyl-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C(C2=CN(C)N=C2)=C1[N+]([O-])=O NEOPMLYYUWCGAK-UHFFFAOYSA-N 0.000 description 1
- LTOXYPBYEIEWNO-UHFFFAOYSA-N 1,3-dibutyl-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2C=C1C=1C=NN(C)C=1 LTOXYPBYEIEWNO-UHFFFAOYSA-N 0.000 description 1
- PBWSWPPSIGNRRD-UHFFFAOYSA-N 1,3-dibutyl-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 PBWSWPPSIGNRRD-UHFFFAOYSA-N 0.000 description 1
- STKIIOJTPIUIBV-UHFFFAOYSA-N 1,3-dibutyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C1[N+]([O-])=O STKIIOJTPIUIBV-UHFFFAOYSA-N 0.000 description 1
- FPNFOKFRQMZCON-UHFFFAOYSA-N 1,3-dibutyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F FPNFOKFRQMZCON-UHFFFAOYSA-N 0.000 description 1
- PUTINCZBICECNT-UHFFFAOYSA-N 1,3-dibutyl-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(C)=C([N+]([O-])=O)C(=O)N(CCCC)C1=O PUTINCZBICECNT-UHFFFAOYSA-N 0.000 description 1
- PULKYJIQBKJPOQ-UHFFFAOYSA-N 1,3-dibutyl-6-methylpyrimidine-2,4-dione Chemical compound CCCCN1C(C)=CC(=O)N(CCCC)C1=O PULKYJIQBKJPOQ-UHFFFAOYSA-N 0.000 description 1
- AJJOHVGQVXLSLY-UHFFFAOYSA-N 1,3-diethyl-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound O=C1N(CC)C(=O)N(CC)C(C2=CN(N=C2)C=2C=CC=CC=2)=C1[N+]([O-])=O AJJOHVGQVXLSLY-UHFFFAOYSA-N 0.000 description 1
- WDARYSYSHWJQIE-UHFFFAOYSA-N 1,3-diethyl-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC)C(=O)N(CC)C(C2=CN(C)N=C2)=C1[N+]([O-])=O WDARYSYSHWJQIE-UHFFFAOYSA-N 0.000 description 1
- UXHBUITXGQEESD-UHFFFAOYSA-N 1,3-diethyl-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2C=C1C=1C=NN(C)C=1 UXHBUITXGQEESD-UHFFFAOYSA-N 0.000 description 1
- MYJTVPNXZFSAPR-UHFFFAOYSA-N 1,3-diethyl-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 MYJTVPNXZFSAPR-UHFFFAOYSA-N 0.000 description 1
- LJQSEYGPDYKUOF-UHFFFAOYSA-N 1,3-diethyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC)C(=O)N(CC)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C1[N+]([O-])=O LJQSEYGPDYKUOF-UHFFFAOYSA-N 0.000 description 1
- KAXFIECSLNITRG-UHFFFAOYSA-N 1,3-diethyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F KAXFIECSLNITRG-UHFFFAOYSA-N 0.000 description 1
- DQAWDNPKOKNXLO-UHFFFAOYSA-N 1,3-diethyl-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound CCN1C(C)=C([N+]([O-])=O)C(=O)N(CC)C1=O DQAWDNPKOKNXLO-UHFFFAOYSA-N 0.000 description 1
- VOUHTHBOMCQORO-UHFFFAOYSA-N 1,3-diethyl-6-methylpyrimidine-2,4-dione Chemical compound CCN1C(C)=CC(=O)N(CC)C1=O VOUHTHBOMCQORO-UHFFFAOYSA-N 0.000 description 1
- AWHORBWDEKTQAX-UHFFFAOYSA-N 1,3-dipropylurea Chemical compound CCCNC(=O)NCCC AWHORBWDEKTQAX-UHFFFAOYSA-N 0.000 description 1
- OTTXHVDIBKLLRP-UHFFFAOYSA-N 1,6-dimethyl-3-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O OTTXHVDIBKLLRP-UHFFFAOYSA-N 0.000 description 1
- SFJJJHPKTFEOFJ-UHFFFAOYSA-N 1,6-dimethyl-5-nitro-3-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(C)C(C)=C([N+]([O-])=O)C(=O)N1CCC1=CC=CC=C1 SFJJJHPKTFEOFJ-UHFFFAOYSA-N 0.000 description 1
- JESJDAQRWZBLPS-UHFFFAOYSA-N 1,6-dimethyl-5-nitro-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(C)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 JESJDAQRWZBLPS-UHFFFAOYSA-N 0.000 description 1
- QLVYFOWDBYKONF-UHFFFAOYSA-N 1,6-dimethyl-5-nitro-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O QLVYFOWDBYKONF-UHFFFAOYSA-N 0.000 description 1
- SOQZVWGBJDACIP-UHFFFAOYSA-N 1-(2-methoxyethyl)-5-nitropyrimidine-2,4-dione Chemical compound COCCN1C=C([N+]([O-])=O)C(=O)NC1=O SOQZVWGBJDACIP-UHFFFAOYSA-N 0.000 description 1
- YKDRELNUTKQCBM-UHFFFAOYSA-N 1-(2-methoxyethyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound COCCN1C(NC(C2=C1C=CN2)=O)=O YKDRELNUTKQCBM-UHFFFAOYSA-N 0.000 description 1
- WFHJULJAKTVDOB-UHFFFAOYSA-N 1-(2-methylpropyl)-3-(2-phenylethyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C=2C=C(C3=CN(N=C3)C=3C=CC=CC=3)NC=2C(=O)N1CCC1=CC=CC=C1 WFHJULJAKTVDOB-UHFFFAOYSA-N 0.000 description 1
- SSHLQZVARPPYCO-UHFFFAOYSA-N 1-(2-methylpropyl)-3-propyl-6-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC(C)C)C=2C=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 SSHLQZVARPPYCO-UHFFFAOYSA-N 0.000 description 1
- KGGDHDNKOKFRTL-UHFFFAOYSA-N 1-(2-methylpropyl)-5-nitro-3-(2-phenylethyl)-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound [O-][N+](=O)C=1C(=O)N(CCC=2C=CC=CC=2)C(=O)N(CC(C)C)C=1C(=C1)C=NN1C1=CC=CC=C1 KGGDHDNKOKFRTL-UHFFFAOYSA-N 0.000 description 1
- JQDQJMVYGAKBLP-UHFFFAOYSA-N 1-(2-methylpropyl)-6-(1-methylpyrazol-4-yl)-3-(2-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C=2C=C(C3=CN(C)N=C3)NC=2C(=O)N1CCC1=CC=CC=C1 JQDQJMVYGAKBLP-UHFFFAOYSA-N 0.000 description 1
- OUSKIGWNQNGFGT-UHFFFAOYSA-N 1-(2-methylpropyl)-6-(1-methylpyrazol-4-yl)-5-nitro-3-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound [O-][N+](=O)C=1C(=O)N(CCC=2C=CC=CC=2)C(=O)N(CC(C)C)C=1C=1C=NN(C)C=1 OUSKIGWNQNGFGT-UHFFFAOYSA-N 0.000 description 1
- VGVNDMFWDLRAFX-UHFFFAOYSA-N 1-(2-phenylethyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1(=CC=CC=C1)CCN1C(NC(C2=C1C=CN2)=O)=O VGVNDMFWDLRAFX-UHFFFAOYSA-N 0.000 description 1
- BKPZQYAGENGGPQ-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound CC1=C([N+]([O-])=O)C(=O)N(C)C(=O)N1CC1CC1 BKPZQYAGENGGPQ-UHFFFAOYSA-N 0.000 description 1
- RKFSDCJAAJZKTE-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-(furan-3-ylmethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC2CC2)C(C)=C([N+]([O-])=O)C(=O)N1CC=1C=COC=1 RKFSDCJAAJZKTE-UHFFFAOYSA-N 0.000 description 1
- HNUVLKOTESZCJX-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-[(4-fluorophenyl)methyl]-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC2CC2)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=C(F)C=C1 HNUVLKOTESZCJX-UHFFFAOYSA-N 0.000 description 1
- BFQBBGRGCBFKOW-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-[(4-methoxyphenyl)methyl]-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC2CC2)C(C)=C([N+]([O-])=O)C1=O BFQBBGRGCBFKOW-UHFFFAOYSA-N 0.000 description 1
- SIMUDSNSEYMURT-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-methoxy-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(OC)C(=O)C([N+]([O-])=O)=C(C)N1CC1CC1 SIMUDSNSEYMURT-UHFFFAOYSA-N 0.000 description 1
- ZMNMWHHEELRPRJ-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-propyl-6-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(CC=4C=C(C=CC=4)C(F)(F)F)N=C3)NC=2C(=O)N(CCC)C(=O)N1CC1CC1 ZMNMWHHEELRPRJ-UHFFFAOYSA-N 0.000 description 1
- SCBQQPJTVYAOFC-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-methyl-3-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)C([N+]([O-])=O)=C(C)N1CC1CC1 SCBQQPJTVYAOFC-UHFFFAOYSA-N 0.000 description 1
- FUDTYABMKORCTB-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-methyl-5-nitro-3-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC2CC2)C(C)=C([N+]([O-])=O)C(=O)N1CCC1=CC=CC=C1 FUDTYABMKORCTB-UHFFFAOYSA-N 0.000 description 1
- ZTPIDRHXWFMLRM-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-methyl-5-nitro-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC2CC2)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 ZTPIDRHXWFMLRM-UHFFFAOYSA-N 0.000 description 1
- SAAZLZSKXMIFTA-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC2=COC=C2)C(C2=CN(N=C2)C=2C=CC=CC=2)=C([N+]([O-])=O)C1=O SAAZLZSKXMIFTA-UHFFFAOYSA-N 0.000 description 1
- ZHTNYZDIGKNBBT-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC2=COC=C2)C(C2=CN(C)N=C2)=C([N+]([O-])=O)C1=O ZHTNYZDIGKNBBT-UHFFFAOYSA-N 0.000 description 1
- MNHAZYFEMPSIHL-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(NC(=C2)C3=CN(C)N=C3)=C2N(CC2=COC=C2)C1=O MNHAZYFEMPSIHL-UHFFFAOYSA-N 0.000 description 1
- VQQQYTPSMOSJCC-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(NC(=C2)C3=CN(N=C3)C=3C=CC=CC=3)=C2N(CC2=COC=C2)C1=O VQQQYTPSMOSJCC-UHFFFAOYSA-N 0.000 description 1
- CBGFILJGDMSSPB-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC2=COC=C2)C(C)=C([N+]([O-])=O)C1=O CBGFILJGDMSSPB-UHFFFAOYSA-N 0.000 description 1
- MBWJJLSTRHDILA-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1NC(=O)C([N+](=O)[O-])=CN1CC1=COC=C1 MBWJJLSTRHDILA-UHFFFAOYSA-N 0.000 description 1
- XOHCGCSNMLOLLO-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound O1C=C(C=C1)CN1C(NC(C2=C1C=CN2)=O)=O XOHCGCSNMLOLLO-UHFFFAOYSA-N 0.000 description 1
- BDXOENMXCIGDKH-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)-5H-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1=CC=C(C=C1)CN1C(NC(C2=C1C=CN2)=O)=O BDXOENMXCIGDKH-UHFFFAOYSA-N 0.000 description 1
- OUKQTRFCDKSEPL-UHFFFAOYSA-N 1-Methyl-2-pyrrolecarboxaldehyde Chemical compound CN1C=CC=C1C=O OUKQTRFCDKSEPL-UHFFFAOYSA-N 0.000 description 1
- KRZNCRHCJCDMPQ-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]pyrazole-4-carbaldehyde Chemical compound FC1=CC=CC=C1CN1N=CC(C=O)=C1 KRZNCRHCJCDMPQ-UHFFFAOYSA-N 0.000 description 1
- YHYMPBULFMAGBW-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]pyrazole-4-carbaldehyde Chemical compound FC1=CC=CC(CN2N=CC(C=O)=C2)=C1 YHYMPBULFMAGBW-UHFFFAOYSA-N 0.000 description 1
- LQOMVXFGKOPRBF-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]pyrazole-4-carbaldehyde Chemical compound COC1=CC=CC(CN2N=CC(C=O)=C2)=C1 LQOMVXFGKOPRBF-UHFFFAOYSA-N 0.000 description 1
- ZEIAZYQPPYTABP-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)NC(=O)C([N+]([O-])=O)=C1 ZEIAZYQPPYTABP-UHFFFAOYSA-N 0.000 description 1
- SCONCZOEWQTMOJ-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-5H-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound COC1=CC=C(CN2C(NC(C3=C2C=CN3)=O)=O)C=C1 SCONCZOEWQTMOJ-UHFFFAOYSA-N 0.000 description 1
- RVSRSMWMTFWNOX-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]pyrazole-4-carbaldehyde Chemical compound C1=CC(C)=CC=C1CN1N=CC(C=O)=C1 RVSRSMWMTFWNOX-UHFFFAOYSA-N 0.000 description 1
- QZSPXAXZMWZHNB-UHFFFAOYSA-N 1-[fluoro(phenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound FC(C1=CC=CC=C1)N1C(NC(C(=C1)[N+](=O)[O-])=O)=O QZSPXAXZMWZHNB-UHFFFAOYSA-N 0.000 description 1
- PFPUKIIFLSSNKL-UHFFFAOYSA-N 1-[fluoro(phenyl)methyl]-5H-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC(C1=CC=CC=C1)N1C(NC(C2=C1C=CN2)=O)=O PFPUKIIFLSSNKL-UHFFFAOYSA-N 0.000 description 1
- FVORUJLQSZNKAS-UHFFFAOYSA-N 1-butyl-3-(2-methylpropyl)-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CCCC)C(C2=CN(N=C2)C=2C=CC=CC=2)=C1[N+]([O-])=O FVORUJLQSZNKAS-UHFFFAOYSA-N 0.000 description 1
- QJNNMQYXRHVGMJ-UHFFFAOYSA-N 1-butyl-3-(2-methylpropyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CCCC)C(C2=CN(C)N=C2)=C1[N+]([O-])=O QJNNMQYXRHVGMJ-UHFFFAOYSA-N 0.000 description 1
- GCLGGMRQTKKAOP-UHFFFAOYSA-N 1-butyl-3-(2-methylpropyl)-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CCCC)C=2C=C1C=1C=NN(C)C=1 GCLGGMRQTKKAOP-UHFFFAOYSA-N 0.000 description 1
- MMDVJMWNVZOCDG-UHFFFAOYSA-N 1-butyl-3-(2-methylpropyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CCCC)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 MMDVJMWNVZOCDG-UHFFFAOYSA-N 0.000 description 1
- NAEVUHMPXSVZBD-UHFFFAOYSA-N 1-butyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CCCC)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C1[N+]([O-])=O NAEVUHMPXSVZBD-UHFFFAOYSA-N 0.000 description 1
- WAOQUAIDCGKMOW-UHFFFAOYSA-N 1-butyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(2-methylpropyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CCCC)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F WAOQUAIDCGKMOW-UHFFFAOYSA-N 0.000 description 1
- INKWSLVWTNYBRO-UHFFFAOYSA-N 1-butyl-6-methyl-3-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(C)=C([N+]([O-])=O)C(=O)N(CC(C)C)C1=O INKWSLVWTNYBRO-UHFFFAOYSA-N 0.000 description 1
- PHZJKJJNGFVIRB-UHFFFAOYSA-N 1-cyclobutyl-5-nitro-6-(1-phenylpyrazol-4-yl)-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C1CCC1N1C(=O)N(CC=2C=CN=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1C1=CC=CC=C1 PHZJKJJNGFVIRB-UHFFFAOYSA-N 0.000 description 1
- JZEOYCAXSSHKHR-UHFFFAOYSA-N 1-cyclobutyl-6-(1-methylpyrazol-4-yl)-3-(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N1)=CC2=C1C(=O)N(CC=1C=CN=CC=1)C(=O)N2C1CCC1 JZEOYCAXSSHKHR-UHFFFAOYSA-N 0.000 description 1
- YGOGNKANKCWFTE-UHFFFAOYSA-N 1-cyclobutyl-6-(1-methylpyrazol-4-yl)-5-nitro-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)C2CCC2)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 YGOGNKANKCWFTE-UHFFFAOYSA-N 0.000 description 1
- QLRLYGXHVLGVLV-UHFFFAOYSA-N 1-cyclobutyl-6-(1-phenylpyrazol-4-yl)-3-(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound O=C1C=2NC(C3=CN(N=C3)C=3C=CC=CC=3)=CC=2N(C2CCC2)C(=O)N1CC1=CC=NC=C1 QLRLYGXHVLGVLV-UHFFFAOYSA-N 0.000 description 1
- BELSSXSEDMAJIB-UHFFFAOYSA-N 1-cyclobutyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(CC=4C=CN=CC=4)C(=O)N(C4CCC4)C=3C=2)=C1 BELSSXSEDMAJIB-UHFFFAOYSA-N 0.000 description 1
- GJVJCTSOVQORMG-UHFFFAOYSA-N 1-cyclobutyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitro-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C1CCC1N1C(=O)N(CC=2C=CN=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F GJVJCTSOVQORMG-UHFFFAOYSA-N 0.000 description 1
- ISMPWQDJSKZSIS-UHFFFAOYSA-N 1-cyclobutyl-6-methyl-5-nitro-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(C2CCC2)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 ISMPWQDJSKZSIS-UHFFFAOYSA-N 0.000 description 1
- WCBQCUWTZNGFIP-UHFFFAOYSA-N 1-cyclopropyl-3-ethyl-5,6-dimethyl-5-nitro-1,3-diazinane-2,4-dione Chemical compound CC1C(C)([N+]([O-])=O)C(=O)N(CC)C(=O)N1C1CC1 WCBQCUWTZNGFIP-UHFFFAOYSA-N 0.000 description 1
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
- ZUKJMDIXSDYEST-UHFFFAOYSA-N 1-ethyl-5-nitro-6-(1-phenylpyrazol-4-yl)-3-propylpyrimidine-2,4-dione Chemical compound CCN1C(=O)N(CCC)C(=O)C([N+]([O-])=O)=C1C1=CN(C=2C=CC=CC=2)N=C1 ZUKJMDIXSDYEST-UHFFFAOYSA-N 0.000 description 1
- NXQFYWRFRIMAME-UHFFFAOYSA-N 1-ethyl-6-(1-methylpyrazol-4-yl)-3-propyl-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2C=C1C=1C=NN(C)C=1 NXQFYWRFRIMAME-UHFFFAOYSA-N 0.000 description 1
- IFDBTJQBARSWKE-UHFFFAOYSA-N 1-ethyl-6-(1-methylpyrazol-4-yl)-5-nitro-3-propylpyrimidine-2,4-dione Chemical compound CCN1C(=O)N(CCC)C(=O)C([N+]([O-])=O)=C1C1=CN(C)N=C1 IFDBTJQBARSWKE-UHFFFAOYSA-N 0.000 description 1
- ABRZWOPZCMZUSG-UHFFFAOYSA-N 1-ethyl-6-(1-phenylpyrazol-4-yl)-3-propyl-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 ABRZWOPZCMZUSG-UHFFFAOYSA-N 0.000 description 1
- XEVCCUZSLDVTHO-UHFFFAOYSA-N 1-ethyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-propyl-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F XEVCCUZSLDVTHO-UHFFFAOYSA-N 0.000 description 1
- LZEILPQYRNBWFD-UHFFFAOYSA-N 1-ethyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitro-3-propylpyrimidine-2,4-dione Chemical compound CCN1C(=O)N(CCC)C(=O)C([N+]([O-])=O)=C1C1=CN(CC=2C(=CC=CC=2)F)N=C1 LZEILPQYRNBWFD-UHFFFAOYSA-N 0.000 description 1
- VKTFENYDKLFMGT-UHFFFAOYSA-N 1-methyl-3-propyl-6-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(C)C=2C=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 VKTFENYDKLFMGT-UHFFFAOYSA-N 0.000 description 1
- MYFZXSOYJVWTBL-UHFFFAOYSA-N 1-methylpyrazole-4-carbaldehyde Chemical compound CN1C=C(C=O)C=N1 MYFZXSOYJVWTBL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PHVRLPFVPVKYOI-UHFFFAOYSA-N 1-phenylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C=NN1C1=CC=CC=C1 PHVRLPFVPVKYOI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- DFHCXFWCDLBFRZ-UHFFFAOYSA-N 3,6-dimethyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CC(C)CN1C(C)=C([N+]([O-])=O)C(=O)N(C)C1=O DFHCXFWCDLBFRZ-UHFFFAOYSA-N 0.000 description 1
- CFADSIBRSRZBQO-UHFFFAOYSA-N 3,6-dimethyl-1h-pyrimidine-2,4-dione Chemical compound CC1=CC(=O)N(C)C(O)=N1 CFADSIBRSRZBQO-UHFFFAOYSA-N 0.000 description 1
- TWTDBGBBAHKLBT-UHFFFAOYSA-N 3,6-dimethyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CC=1NC(=O)N(C)C(=O)C=1[N+]([O-])=O TWTDBGBBAHKLBT-UHFFFAOYSA-N 0.000 description 1
- UUWSOKJEJHCDHZ-UHFFFAOYSA-N 3-(2-methoxyethyl)-5-nitro-6-(1-phenylpyrazol-4-yl)-1-propylpyrimidine-2,4-dione Chemical compound O=C1N(CCOC)C(=O)N(CCC)C(C2=CN(N=C2)C=2C=CC=CC=2)=C1[N+]([O-])=O UUWSOKJEJHCDHZ-UHFFFAOYSA-N 0.000 description 1
- LIACUSNJPDVORJ-UHFFFAOYSA-N 3-(2-methoxyethyl)-6-(1-methylpyrazol-4-yl)-1-propyl-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCOC)C(=O)N(CCC)C=2C=C1C=1C=NN(C)C=1 LIACUSNJPDVORJ-UHFFFAOYSA-N 0.000 description 1
- LOIROUIVNLIDLJ-UHFFFAOYSA-N 3-(2-methoxyethyl)-6-(1-methylpyrazol-4-yl)-5-nitro-1-propylpyrimidine-2,4-dione Chemical compound O=C1N(CCOC)C(=O)N(CCC)C(C2=CN(C)N=C2)=C1[N+]([O-])=O LOIROUIVNLIDLJ-UHFFFAOYSA-N 0.000 description 1
- OZBJYMKQROIBRE-UHFFFAOYSA-N 3-(2-methoxyethyl)-6-(1-phenylpyrazol-4-yl)-1-propyl-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCOC)C(=O)N(CCC)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 OZBJYMKQROIBRE-UHFFFAOYSA-N 0.000 description 1
- BZOBQONVBIUJIG-UHFFFAOYSA-N 3-(2-methoxyethyl)-6-methyl-5-nitro-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(C)=C([N+]([O-])=O)C(=O)N(CCOC)C1=O BZOBQONVBIUJIG-UHFFFAOYSA-N 0.000 description 1
- PPJZAEMOVUQUDM-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(C)C(C)=C([N+]([O-])=O)C(=O)N1CC1=COC=C1 PPJZAEMOVUQUDM-UHFFFAOYSA-N 0.000 description 1
- APIROINIBTWQQR-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-5-nitro-6-(1-phenylpyrazol-4-yl)-1-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C=1C=NC=CC=1CN1C(=O)N(CC2=COC=C2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1C1=CC=CC=C1 APIROINIBTWQQR-UHFFFAOYSA-N 0.000 description 1
- RPJWNRXODFSCDC-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-6-(1-methylpyrazol-4-yl)-1-(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N1)=CC2=C1C(=O)N(CC1=COC=C1)C(=O)N2CC1=CC=NC=C1 RPJWNRXODFSCDC-UHFFFAOYSA-N 0.000 description 1
- BBHABFNMDZPGKG-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-6-(1-methylpyrazol-4-yl)-5-nitro-1-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)CC=2C=CN=CC=2)=C([N+]([O-])=O)C(=O)N1CC1=COC=C1 BBHABFNMDZPGKG-UHFFFAOYSA-N 0.000 description 1
- QTAUMXOFYKIRDV-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-6-(1-phenylpyrazol-4-yl)-1-(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(N=C3)C=3C=CC=CC=3)NC=2C(=O)N(CC2=COC=C2)C(=O)N1CC1=CC=NC=C1 QTAUMXOFYKIRDV-UHFFFAOYSA-N 0.000 description 1
- YQCWYVHXFFWIBP-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(C)=C([N+]([O-])=O)C(=O)N1CC1=COC=C1 YQCWYVHXFFWIBP-UHFFFAOYSA-N 0.000 description 1
- YTTVHEKWOMYZFW-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-6-methyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1CC1=COC=C1 YTTVHEKWOMYZFW-UHFFFAOYSA-N 0.000 description 1
- WSDLBJNAQCGXJF-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-6-methyl-5-nitro-1-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CN=CC=2)C(C)=C([N+]([O-])=O)C(=O)N1CC=1C=COC=1 WSDLBJNAQCGXJF-UHFFFAOYSA-N 0.000 description 1
- UDDXELMPMIRFGL-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1CC1=COC=C1 UDDXELMPMIRFGL-UHFFFAOYSA-N 0.000 description 1
- BPBJRLJVNRFTLF-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(C)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=C(F)C=C1 BPBJRLJVNRFTLF-UHFFFAOYSA-N 0.000 description 1
- DUXSGZYYFMTEJU-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=C(F)C=C1 DUXSGZYYFMTEJU-UHFFFAOYSA-N 0.000 description 1
- CNGBXLODSCMQLF-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-6-methyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1CC1=CC=C(F)C=C1 CNGBXLODSCMQLF-UHFFFAOYSA-N 0.000 description 1
- OCOGJLZYYKREIY-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1CC1=CC=C(F)C=C1 OCOGJLZYYKREIY-UHFFFAOYSA-N 0.000 description 1
- DLHDFYUZSMICIF-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methyl]-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C)C(C)=C([N+]([O-])=O)C1=O DLHDFYUZSMICIF-UHFFFAOYSA-N 0.000 description 1
- CTLYFFBZCPOSND-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methyl]-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC(C)C)C(C)=C([N+]([O-])=O)C1=O CTLYFFBZCPOSND-UHFFFAOYSA-N 0.000 description 1
- NXEOXNRFOGQQBA-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methyl]-6-methyl-1h-pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)NC(C)=CC1=O NXEOXNRFOGQQBA-UHFFFAOYSA-N 0.000 description 1
- JUSCYVOYQCDAHU-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methyl]-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C([N+]([O-])=O)=C(C)NC1=O JUSCYVOYQCDAHU-UHFFFAOYSA-N 0.000 description 1
- YODKGOKWKOWPSN-UHFFFAOYSA-N 3-[fluoro(phenyl)methyl]-1-[(4-methoxyphenyl)methyl]-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(C=2C=CC=CC=2)N=C1 YODKGOKWKOWPSN-UHFFFAOYSA-N 0.000 description 1
- YZCFMBXEQLOAAV-UHFFFAOYSA-N 3-[fluoro(phenyl)methyl]-1-[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(C)N=C1 YZCFMBXEQLOAAV-UHFFFAOYSA-N 0.000 description 1
- RNEJAAGMVGKFNS-UHFFFAOYSA-N 3-[fluoro(phenyl)methyl]-1-[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C2=C1C=C(C1=CN(C)N=C1)N2 RNEJAAGMVGKFNS-UHFFFAOYSA-N 0.000 description 1
- CZIDIUZYDKJBRC-UHFFFAOYSA-N 3-[fluoro(phenyl)methyl]-1-[(4-methoxyphenyl)methyl]-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C2=C1C=C(C1=CN(N=C1)C=1C=CC=CC=1)N2 CZIDIUZYDKJBRC-UHFFFAOYSA-N 0.000 description 1
- QQSSKPBIJHMUNX-UHFFFAOYSA-N 3-[fluoro(phenyl)methyl]-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-[(4-methoxyphenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(CC=2C(=CC=CC=2)F)N=C1 QQSSKPBIJHMUNX-UHFFFAOYSA-N 0.000 description 1
- NXXVZNVDWDWLKU-UHFFFAOYSA-N 3-[fluoro(phenyl)methyl]-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-[(4-methoxyphenyl)methyl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C2=C1C=C(C1=CN(CC=3C(=CC=CC=3)F)N=C1)N2 NXXVZNVDWDWLKU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CNZGWEWAMHKLKL-UHFFFAOYSA-N 3-butyl-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O CNZGWEWAMHKLKL-UHFFFAOYSA-N 0.000 description 1
- JBMLQKGBQAPARE-UHFFFAOYSA-N 3-butyl-1-(1-methoxyethyl)-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound COC(C)N1C(=O)N(CCCC)C(=O)C([N+]([O-])=O)=C1C1=CN(C=2C=CC=CC=2)N=C1 JBMLQKGBQAPARE-UHFFFAOYSA-N 0.000 description 1
- VZQCEMSAERJBES-UHFFFAOYSA-N 3-butyl-1-(1-methoxyethyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound COC(C)N1C(=O)N(CCCC)C(=O)C([N+]([O-])=O)=C1C1=CN(C)N=C1 VZQCEMSAERJBES-UHFFFAOYSA-N 0.000 description 1
- XCOOFMYXCRCTRX-UHFFFAOYSA-N 3-butyl-1-(1-methoxyethyl)-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(C(C)OC)C=2C=C1C=1C=NN(C)C=1 XCOOFMYXCRCTRX-UHFFFAOYSA-N 0.000 description 1
- HGWWMARZDNOPDQ-UHFFFAOYSA-N 3-butyl-1-(1-methoxyethyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(C(C)OC)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 HGWWMARZDNOPDQ-UHFFFAOYSA-N 0.000 description 1
- PVNVFFKJNHFRNO-UHFFFAOYSA-N 3-butyl-1-(1-methoxyethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C([N+]([O-])=O)=C(C)N(C(C)OC)C1=O PVNVFFKJNHFRNO-UHFFFAOYSA-N 0.000 description 1
- FTFOQTFCZNUKLB-UHFFFAOYSA-N 3-butyl-1-(cyclopropylmethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CCCC)C(=O)C([N+]([O-])=O)=C(C)N1CC1CC1 FTFOQTFCZNUKLB-UHFFFAOYSA-N 0.000 description 1
- VZGWWJBRKINXLH-UHFFFAOYSA-N 3-butyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(1-methoxyethyl)-5-nitropyrimidine-2,4-dione Chemical compound COC(C)N1C(=O)N(CCCC)C(=O)C([N+]([O-])=O)=C1C1=CN(CC=2C(=CC=CC=2)F)N=C1 VZGWWJBRKINXLH-UHFFFAOYSA-N 0.000 description 1
- QYNYCNOCURYFGX-UHFFFAOYSA-N 3-butyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(1-methoxyethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(C(C)OC)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F QYNYCNOCURYFGX-UHFFFAOYSA-N 0.000 description 1
- OGHJMIINFMBEON-UHFFFAOYSA-N 3-butyl-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C([N+]([O-])=O)=C(C)N(CC(C)C)C1=O OGHJMIINFMBEON-UHFFFAOYSA-N 0.000 description 1
- QRGVGZWQHXGOFJ-UHFFFAOYSA-N 3-butyl-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C=C(C)NC1=O QRGVGZWQHXGOFJ-UHFFFAOYSA-N 0.000 description 1
- XNEORMFBOGTRLE-UHFFFAOYSA-N 3-butyl-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CCCCN1C(=O)NC(C)=C([N+]([O-])=O)C1=O XNEORMFBOGTRLE-UHFFFAOYSA-N 0.000 description 1
- VCPQEQRHFPJTSN-UHFFFAOYSA-N 3-cyclobutyl-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(C)C(C)=C([N+]([O-])=O)C(=O)N1C1CCC1 VCPQEQRHFPJTSN-UHFFFAOYSA-N 0.000 description 1
- VUFWTIBYFNJYRU-UHFFFAOYSA-N 3-cyclobutyl-1-(1-phenylethyl)-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(N=C3)C=3C=CC=CC=3)NC=2C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 VUFWTIBYFNJYRU-UHFFFAOYSA-N 0.000 description 1
- NJBLZGMFMAWKCL-UHFFFAOYSA-N 3-cyclobutyl-1-(cyclopropylmethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC2CC2)C(C)=C([N+]([O-])=O)C(=O)N1C1CCC1 NJBLZGMFMAWKCL-UHFFFAOYSA-N 0.000 description 1
- ZTQHFMUCIMYDMN-UHFFFAOYSA-N 3-cyclobutyl-5-nitro-1-(1-phenylethyl)-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C1=NN(C=2C=CC=CC=2)C=C1C1=C([N+]([O-])=O)C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 ZTQHFMUCIMYDMN-UHFFFAOYSA-N 0.000 description 1
- MCQAFSAVIAKSJZ-UHFFFAOYSA-N 3-cyclobutyl-6-(1-methylpyrazol-4-yl)-1-(1-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(C)N=C3)NC=2C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 MCQAFSAVIAKSJZ-UHFFFAOYSA-N 0.000 description 1
- SWNZHHUHYVTDBP-UHFFFAOYSA-N 3-cyclobutyl-6-(1-methylpyrazol-4-yl)-5-nitro-1-(1-phenylethyl)pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C1=C([N+]([O-])=O)C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 SWNZHHUHYVTDBP-UHFFFAOYSA-N 0.000 description 1
- XKMRROJXXBMHAJ-UHFFFAOYSA-N 3-cyclobutyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(1-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(CC=4C(=CC=CC=4)F)N=C3)NC=2C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 XKMRROJXXBMHAJ-UHFFFAOYSA-N 0.000 description 1
- CEWVKDMBUVNFQT-UHFFFAOYSA-N 3-cyclobutyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitro-1-(1-phenylethyl)pyrimidine-2,4-dione Chemical compound C1=NN(CC=2C(=CC=CC=2)F)C=C1C1=C([N+]([O-])=O)C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 CEWVKDMBUVNFQT-UHFFFAOYSA-N 0.000 description 1
- FNFQGLSDWCRHQA-UHFFFAOYSA-N 3-cyclobutyl-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(C)=C([N+]([O-])=O)C(=O)N1C1CCC1 FNFQGLSDWCRHQA-UHFFFAOYSA-N 0.000 description 1
- QFKNUYPFPUAGRO-UHFFFAOYSA-N 3-cyclobutyl-6-methyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1C1CCC1 QFKNUYPFPUAGRO-UHFFFAOYSA-N 0.000 description 1
- DKDMASXBYDGTPZ-UHFFFAOYSA-N 3-cyclobutyl-6-methyl-5-nitro-1-(1-phenylethyl)pyrimidine-2,4-dione Chemical compound CC1=C([N+]([O-])=O)C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 DKDMASXBYDGTPZ-UHFFFAOYSA-N 0.000 description 1
- SPXWSECEOXTYES-UHFFFAOYSA-N 3-cyclobutyl-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1C1CCC1 SPXWSECEOXTYES-UHFFFAOYSA-N 0.000 description 1
- ILUSPSNUTUYRGL-UHFFFAOYSA-N 3-ethyl-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CCN1C(=O)C([N+]([O-])=O)=C(C)N(CC(C)C)C1=O ILUSPSNUTUYRGL-UHFFFAOYSA-N 0.000 description 1
- VWPISPCRFQVXQX-UHFFFAOYSA-N 3-ethyl-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CCN1C(=O)C=C(C)NC1=O VWPISPCRFQVXQX-UHFFFAOYSA-N 0.000 description 1
- NCMSOYCKJGJZKB-UHFFFAOYSA-N 3-ethyl-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CCN1C(=O)NC(C)=C([N+]([O-])=O)C1=O NCMSOYCKJGJZKB-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- LOGOEBMHHXYBID-MOROJQBDSA-N 3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C(N)=CC=3)=C2N=C1 LOGOEBMHHXYBID-MOROJQBDSA-N 0.000 description 1
- OVVCUISFVNHUIC-UHFFFAOYSA-N 3-methoxy-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound CON1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O OVVCUISFVNHUIC-UHFFFAOYSA-N 0.000 description 1
- QENAXQZVSHKWOP-UHFFFAOYSA-N 3-methoxy-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CON1C(=O)C([N+]([O-])=O)=C(C)N(CC(C)C)C1=O QENAXQZVSHKWOP-UHFFFAOYSA-N 0.000 description 1
- SZHSZJKDZQMRCH-UHFFFAOYSA-N 3-methoxy-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CON1C(=O)C=C(C)NC1=O SZHSZJKDZQMRCH-UHFFFAOYSA-N 0.000 description 1
- YNNIMFMDUDBFBV-UHFFFAOYSA-N 3-methoxy-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CON1C(=O)NC(C)=C([N+]([O-])=O)C1=O YNNIMFMDUDBFBV-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VTDHTWMJWWAYCH-UHFFFAOYSA-N 5-nitro-1,3-bis(2-phenylethyl)-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C=1C=CC=CC=1CCN1C(=O)N(CCC=2C=CC=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1C1=CC=CC=C1 VTDHTWMJWWAYCH-UHFFFAOYSA-N 0.000 description 1
- SRPGQMNBYIWIDQ-UHFFFAOYSA-N 5-nitro-1-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C([N+](=O)[O-])=CN1CCC1=CC=CC=C1 SRPGQMNBYIWIDQ-UHFFFAOYSA-N 0.000 description 1
- DFWNRDDOVMFIAX-UHFFFAOYSA-N 5-nitro-1-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C([N+](=O)[O-])=CN1CC1=CC=NC=C1 DFWNRDDOVMFIAX-UHFFFAOYSA-N 0.000 description 1
- LCKLKMOAMXXLEP-UHFFFAOYSA-N 5-nitro-6-(1-phenylpyrazol-4-yl)-1,3-bis(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C=1C=NC=CC=1CN1C(=O)N(CC=2C=CN=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1C1=CC=CC=C1 LCKLKMOAMXXLEP-UHFFFAOYSA-N 0.000 description 1
- TUARVSWVPPVUGS-UHFFFAOYSA-N 5-nitrouracil Chemical group [O-][N+](=O)C1=CNC(=O)NC1=O TUARVSWVPPVUGS-UHFFFAOYSA-N 0.000 description 1
- ICENILRKNUKRPB-UHFFFAOYSA-N 5-thiophen-2-yl-1,2-oxazole-3-carbaldehyde Chemical compound O1N=C(C=O)C=C1C1=CC=CS1 ICENILRKNUKRPB-UHFFFAOYSA-N 0.000 description 1
- POCXXOZDWANFND-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-1,3-bis(2-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N1)=CC2=C1C(=O)N(CCC=1C=CC=CC=1)C(=O)N2CCC1=CC=CC=C1 POCXXOZDWANFND-UHFFFAOYSA-N 0.000 description 1
- GFQOLVDDFOUIMA-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-1,3-bis(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N1)=CC2=C1C(=O)N(CC=1C=CN=CC=1)C(=O)N2CC1=CC=NC=C1 GFQOLVDDFOUIMA-UHFFFAOYSA-N 0.000 description 1
- BFFWWHHVRSSASR-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-5-nitro-1,3-bis(2-phenylethyl)pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)CCC=2C=CC=CC=2)=C([N+]([O-])=O)C(=O)N1CCC1=CC=CC=C1 BFFWWHHVRSSASR-UHFFFAOYSA-N 0.000 description 1
- SJSVBIFTPHRLLC-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-5-nitro-1,3-bis(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)CC=2C=CN=CC=2)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 SJSVBIFTPHRLLC-UHFFFAOYSA-N 0.000 description 1
- UVYYASRPKDHKSF-UHFFFAOYSA-N 6-(1-phenylpyrazol-4-yl)-1,3-bis(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(N=C3)C=3C=CC=CC=3)NC=2C(=O)N(CC=2C=CN=CC=2)C(=O)N1CC1=CC=NC=C1 UVYYASRPKDHKSF-UHFFFAOYSA-N 0.000 description 1
- IINJNTBUEAYGJX-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(2-methoxyethyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CCOC)C(=O)N(CCOC)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C1[N+]([O-])=O IINJNTBUEAYGJX-UHFFFAOYSA-N 0.000 description 1
- MGNNJTKQRTVPSI-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(2-methoxyethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCOC)C(=O)N(CCOC)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F MGNNJTKQRTVPSI-UHFFFAOYSA-N 0.000 description 1
- WRAQELHVSDYTGU-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CC(C)C)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C1[N+]([O-])=O WRAQELHVSDYTGU-UHFFFAOYSA-N 0.000 description 1
- ZESTXYNUNHMPRA-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(2-methylpropyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CC(C)C)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F ZESTXYNUNHMPRA-UHFFFAOYSA-N 0.000 description 1
- GWSXPWAQIOKOMO-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(2-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(CCC=4C=CC=CC=4)C(=O)N(CCC=4C=CC=CC=4)C=3C=2)=C1 GWSXPWAQIOKOMO-UHFFFAOYSA-N 0.000 description 1
- HKWYSBGLWUANDC-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(furan-3-ylmethyl)-5-nitropyrimidine-2,4-dione Chemical compound C1=COC=C1CN1C(=O)N(CC2=COC=C2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F HKWYSBGLWUANDC-UHFFFAOYSA-N 0.000 description 1
- DRGOFCBWNVOQIT-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(furan-3-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(CC4=COC=C4)C(=O)N(CC4=COC=C4)C=3C=2)=C1 DRGOFCBWNVOQIT-UHFFFAOYSA-N 0.000 description 1
- CXFWYCUJFPONGA-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(CC=4C=CN=CC=4)C(=O)N(CC=4C=CN=CC=4)C=3C=2)=C1 CXFWYCUJFPONGA-UHFFFAOYSA-N 0.000 description 1
- LOXKBMGLJGGTGG-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis[(4-methoxyphenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(CC=2C(=CC=CC=2)F)N=C1 LOXKBMGLJGGTGG-UHFFFAOYSA-N 0.000 description 1
- SQZDEAFIJBDRSX-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis[(4-methoxyphenyl)methyl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C2=C1C=C(C1=CN(CC=3C(=CC=CC=3)F)N=C1)N2 SQZDEAFIJBDRSX-UHFFFAOYSA-N 0.000 description 1
- QWXVBMHJAPPSSO-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(2-methylpropyl)-3-(2-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C=2C=C(C3=CN(CC=4C(=CC=CC=4)F)N=C3)NC=2C(=O)N1CCC1=CC=CC=C1 QWXVBMHJAPPSSO-UHFFFAOYSA-N 0.000 description 1
- CSZAGZVXCRYTTM-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(2-methylpropyl)-5-nitro-3-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound [O-][N+](=O)C=1C(=O)N(CCC=2C=CC=CC=2)C(=O)N(CC(C)C)C=1C(=C1)C=NN1CC1=CC=CC=C1F CSZAGZVXCRYTTM-UHFFFAOYSA-N 0.000 description 1
- QHGLRIQJSXCDLJ-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC2=COC=C2)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C([N+]([O-])=O)C1=O QHGLRIQJSXCDLJ-UHFFFAOYSA-N 0.000 description 1
- LEMUENPFUGBXMO-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(NC(=C2)C3=CN(CC=4C(=CC=CC=4)F)N=C3)=C2N(CC2=COC=C2)C1=O LEMUENPFUGBXMO-UHFFFAOYSA-N 0.000 description 1
- TYYJIPPPHPIMMB-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(2-methoxyethyl)-1-propyl-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCOC)C(=O)N(CCC)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F TYYJIPPPHPIMMB-UHFFFAOYSA-N 0.000 description 1
- PTMXILVXMFJGHP-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(2-methoxyethyl)-5-nitro-1-propylpyrimidine-2,4-dione Chemical compound O=C1N(CCOC)C(=O)N(CCC)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C1[N+]([O-])=O PTMXILVXMFJGHP-UHFFFAOYSA-N 0.000 description 1
- DEKUELWDRSVHSP-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(furan-3-ylmethyl)-1-(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(CC4=COC=C4)C(=O)N(CC=4C=CN=CC=4)C=3C=2)=C1 DEKUELWDRSVHSP-UHFFFAOYSA-N 0.000 description 1
- BUYYEHYZDANIPX-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(furan-3-ylmethyl)-5-nitro-1-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C=1C=NC=CC=1CN1C(=O)N(CC2=COC=C2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F BUYYEHYZDANIPX-UHFFFAOYSA-N 0.000 description 1
- FPBGISRCGDPFKI-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitro-1,3-bis(2-phenylethyl)pyrimidine-2,4-dione Chemical compound C=1C=CC=CC=1CCN1C(=O)N(CCC=2C=CC=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F FPBGISRCGDPFKI-UHFFFAOYSA-N 0.000 description 1
- KYVAKYXMLBSHCJ-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitro-1,3-bis(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C=1C=NC=CC=1CN1C(=O)N(CC=2C=CN=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F KYVAKYXMLBSHCJ-UHFFFAOYSA-N 0.000 description 1
- UIIPRHMXBRNECY-UHFFFAOYSA-N 6-methyl-1,3-bis(2-methylpropyl)pyrimidine-2,4-dione Chemical compound CC(C)CN1C(C)=CC(=O)N(CC(C)C)C1=O UIIPRHMXBRNECY-UHFFFAOYSA-N 0.000 description 1
- FVQNFEJKQGWUCI-UHFFFAOYSA-N 6-methyl-1,3-bis(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CCC=2C=CC=CC=2)C(C)=CC(=O)N1CCC1=CC=CC=C1 FVQNFEJKQGWUCI-UHFFFAOYSA-N 0.000 description 1
- JYUJMPFZSQBOAT-UHFFFAOYSA-N 6-methyl-1,3-bis(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CN=CC=2)C(C)=CC(=O)N1CC1=CC=NC=C1 JYUJMPFZSQBOAT-UHFFFAOYSA-N 0.000 description 1
- OQYDYTOYFQIJSY-UHFFFAOYSA-N 6-methyl-1,3-bis[[4-(trifluoromethyl)phenyl]methyl]pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CC(=CC=2)C(F)(F)F)C(C)=CC(=O)N1CC1=CC=C(C(F)(F)F)C=C1 OQYDYTOYFQIJSY-UHFFFAOYSA-N 0.000 description 1
- VYMKNYBJCRYBLW-UHFFFAOYSA-N 6-methyl-1-(2-methylpropyl)-5-nitro-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 VYMKNYBJCRYBLW-UHFFFAOYSA-N 0.000 description 1
- FMRWAKZUWFOTDM-UHFFFAOYSA-N 6-methyl-3-(2-methylpropyl)-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)C=C(C)NC1=O FMRWAKZUWFOTDM-UHFFFAOYSA-N 0.000 description 1
- ARTLAARPNPCNMT-UHFFFAOYSA-N 6-methyl-3-(2-methylpropyl)-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)NC(C)=C([N+]([O-])=O)C1=O ARTLAARPNPCNMT-UHFFFAOYSA-N 0.000 description 1
- PECQEDXEQILCQR-UHFFFAOYSA-N 6-methyl-3-(2-phenylethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1CCC1=CC=CC=C1 PECQEDXEQILCQR-UHFFFAOYSA-N 0.000 description 1
- LPPDCBVWQDSQGL-UHFFFAOYSA-N 6-methyl-3-(pyridin-4-ylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1CC1=CC=NC=C1 LPPDCBVWQDSQGL-UHFFFAOYSA-N 0.000 description 1
- DLVWXMBDUOXIMR-UHFFFAOYSA-N 6-methyl-5-nitro-1,3-bis(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CCC=2C=CC=CC=2)C(C)=C([N+]([O-])=O)C(=O)N1CCC1=CC=CC=C1 DLVWXMBDUOXIMR-UHFFFAOYSA-N 0.000 description 1
- UCADQQLVCUVULT-UHFFFAOYSA-N 6-methyl-5-nitro-1,3-bis(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CN=CC=2)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 UCADQQLVCUVULT-UHFFFAOYSA-N 0.000 description 1
- AHWXWCXUIRGJNQ-UHFFFAOYSA-N 6-methyl-5-nitro-1,3-bis[[4-(trifluoromethyl)phenyl]methyl]pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CC(=CC=2)C(F)(F)F)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=C(C(F)(F)F)C=C1 AHWXWCXUIRGJNQ-UHFFFAOYSA-N 0.000 description 1
- YPWSNQAQWNMIAP-UHFFFAOYSA-N 6-methyl-5-nitro-3-(2-phenylethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1CCC1=CC=CC=C1 YPWSNQAQWNMIAP-UHFFFAOYSA-N 0.000 description 1
- ZCNBUVAIUWDBSB-UHFFFAOYSA-N 6-methyl-5-nitro-3-(pyridin-4-ylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1CC1=CC=NC=C1 ZCNBUVAIUWDBSB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- DYEHECHBGDRWAO-UHFFFAOYSA-N COC1C(=CN(CN1C(C2=CC=CC=C2)F)CC3=CC=CC=C3)[N+](=O)[O-] Chemical compound COC1C(=CN(CN1C(C2=CC=CC=C2)F)CC3=CC=CC=C3)[N+](=O)[O-] DYEHECHBGDRWAO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical group CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PRPVFMPCEJBYSB-UHFFFAOYSA-N [1-[(2-fluorophenyl)methyl]pyrazol-4-yl]methanol Chemical compound C1=C(CO)C=NN1CC1=CC=CC=C1F PRPVFMPCEJBYSB-UHFFFAOYSA-N 0.000 description 1
- KRGBOUIZYVNRTD-UHFFFAOYSA-N [1-[(3-methoxyphenyl)methyl]pyrazol-4-yl]methanol Chemical compound COC1=CC=CC(CN2N=CC(CO)=C2)=C1 KRGBOUIZYVNRTD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- SOGAXMICEFXMKE-UHFFFAOYSA-N alpha-Methyl-n-butyl acrylate Natural products CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000588 effect on asthma Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- GXKQVOXCQOQZED-UHFFFAOYSA-N ethyl 1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C)C=1 GXKQVOXCQOQZED-UHFFFAOYSA-N 0.000 description 1
- IIKHONWHFIKUQV-UHFFFAOYSA-N ethyl 1-methylpyrrole-2-carboxylate Chemical compound CCOC(=O)C1=CC=CN1C IIKHONWHFIKUQV-UHFFFAOYSA-N 0.000 description 1
- UBIULDHICQCHJE-UHFFFAOYSA-N ethyl 1-phenylpyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=CC=CC=C1 UBIULDHICQCHJE-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HGUZQMQXAHVIQC-UHFFFAOYSA-N n-methylethenamine Chemical group CNC=C HGUZQMQXAHVIQC-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
A2B受容体アンタゴニストを提供することが、本発明の目的である。従って、第一の態様として、本発明は、式I:
[式中、
R1およびR2は独立して、水素、適宜置換されたアルキル、適宜置換されたシクロアルキル、適宜置換されたアリール、および適宜置換されたヘテロアリールから選択され;
R3は、水素、ヒドロキシ、適宜置換されたアルキル、適宜置換されたシクロアルキル、適宜置換されたアリール、および適宜置換されたヘテロアリールから選択され;および
R4は適宜置換されたヘテロアリール部分であるが、但し、R4は単一のSまたはOヘテロ原子を含む無置換5員単環式ヘテロアリール環ではない]
の化合物に関する。
8−(1−メチル−1H−ピロール−2−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イル)−1−エチル−3−プロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−ベンジル−1H−ピラゾール−4−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−ベンジル−1H−ピラゾール−4−イル)−7−ヒドロキシ−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−(3−フルオロベンジル)−1H−ピラゾール−4−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(ピリジン−4−イル)−7−ヒドロキシ−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(ピリジン−2−イル)−7−ヒドロキシ−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(5−(チオフェン−2−イル)イソキサゾール−3−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イル)−7−ヒドロキシ−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(N−オキシピリジン−4−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
6−(1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イル)−1−メチル−3−プロピル−1H−ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン;
6−(1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イル)−1−シクロプロピルメチル−3−プロピル−1H−ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン;および
6−(1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イル)−1−イソブチル−3−プロピル−1H−ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオンである。
本明細書に用いられる場合、以下の単語および用語は、他に断りがある文脈の範囲を除いて、以下に記述するような意味を有すると一般的に意図される。
1)アルケニル、アルキニル、アルコキシ、シクロアルキル、シクロアルケニル、アシル、アシルアミノ、アシルオキシ、アミノ、アミノカルボニル、アルコキシカルボニルアミノ、アジド、シアノ、ハロゲン、ヒドロキシ、ケト、チオカルボニル、カルボキシ、カルボキシアルキル、アリールチオ、ヘテロアリールチオ、ヘテロサイクリルチオ、チオール、アルキルチオ、アリール、アリールオキシ、ヘテロアリール、アミノスルホニル、アミノカルボニルアミノ、ヘテロアリールオキシ、ヘテロサイクリル、ヘテロシクロオキシ、ヒドロキシアミノ、アルコキシアミノ、ニトロ、−SO−アルキル、−SO−アリール、−SO−ヘテロアリール、−SO2−アルキル、SO2−アリールおよび−SO2−ヘテロアリールからなる群から選択される1、2、3、4または5個の置換基、好ましくは1〜3個の置換基を有する上記で定義されるアルキル基。定義で特に束縛されない限り、すべての置換基はさらに、アルキル、カルボキシ、カルボキシアルキル、アミノカルボニル、ヒドロキシ、アルコキシ、ハロゲン、CF3、アミノ、置換されたアミノ、シアノ、および−S(O)nR(Rはアルキル、アリール、またはヘテロアリールであり、nは0、1または2である)から選択される1、2、または3個の置換基で適宜置換されていてもよく;または
2)酸素、硫黄およびNRa−(Raは、水素、アルキル、シクロアルキル、アルケニル、シクロアルケニル、アルキニル、アリール、ヘテロアリールおよびヘテロサイクリルから選択される)から独立して選択される1〜10個の原子で中断された上記で定義されるアルキル基。すべての置換基はさらに、アルキル、アルコキシ、ハロゲン、CF3、アミノ、置換されたアミノ、シアノ、または−S(O)nR(Rはアルキル、アリール、またはヘテロアリールであり、nは0、1または2である)で適宜置換されていてもよく;または
3)上記で定義されるような1、2、3、4または5個の置換基のいずれも有する上記で定義されるアルキル基であり、上記で定義された1〜10個の原子で中断されてもいる。
(1)アルキル、アルケニル、アルキニル、アルコキシ、シクロアルキル、シクロアルケニル、アシル、アシルアミノ、アシルオキシ、アミノ、アミノカルボニル、アルコキシカルボニルアミノ、アジド、シアノ、ハロゲン、ヒドロキシ、ケト、チオカルボニル、カルボキシ、カルボキシアルキル、アリールチオ、ヘテロアリールチオ、ヘテロサイクリルチオ、チオール、アルキルチオ、アリール、アリールオキシ、ヘテロアリール、アミノスルホニル、アミノカルボニルアミノ、ヘテロアリールオキシ、ヘテロサイクリル、ヘテロシクロオキシ、ヒドロキシアミノ、アルコキシアミノ、ニトロ、−SO−アルキル、−SO−アリール、−SO−ヘテロアリール、−SO2−アルキル、SO2−アリールおよび−SO2−ヘテロアリールからなる群から選択される1、2、3、4、または5個の置換基を有する、上記で定義されるアルキレン基。定義で特に束縛されない限り、すべての置換基はさらに、アルキル、カルボキシ、カルボキシアルキル、アミノカルボニル、ヒドロキシ、アルコキシ、ハロゲン、CF3、アミノ、置換されたアミノ、シアノ、および−S(O)nR(Rはアルキル、アリール、またはヘテロアリールであり、nは0、1または2である)から選択される1、2、または3個の置換基で適宜置換されていてもよく;または
(2)酸素、硫黄およびNRa−(Raは、水素、適宜置換されたアルキル、シクロアルキル、シクロアルケニル、アリール、ヘテロアリールおよびヘテロサイクリルから選択される)から独立して選択される1〜20個の原子で、またはカルボニル、カルボキシエステル、カルボキシアミドおよびスルホニルから選択される基で中断された上記で定義されるアルキレン基;または
(3)上記で定義されるような1、2、3、4または5個の置換基のいずれも有する上記で定義されるアルキレン基であり、上記のように1〜20個の原子で中断されてもいる。置換されたアルキレンの例には、クロロメチレン(−CH(Cl)−)、アミノエチレン(−CH(NH2)CH2−)、メチルアミノエチレン(−CH(NHMe)CH2−)、2−カルボキシプロピレン異性体(−CH2CH(CO2H)CH2−)、エトキシエチル(−CH2CH2O−CH2CH2−)、エチルメチルアミノエチル(−CH2CH2N(CH3)CH2CH2−)、1−エトキシ−2−(2−エトキシ−エトキシ)エタン(−CH2CH2O−CH2CH2−OCH2CH2−OCH2CH2−)などがある。
(i)疾患の予防、すなわち、疾患の臨床上の症状を進行させないこと;
(ii)疾患の阻害、すなわち、臨床上の症状の進行を阻止すること;および/または
(iii)疾患の軽減、すなわち、臨床上の症状の緩解を起こさせること。
本発明の化合物の命名およびナンバーリングは、下記の式Iの代表的化合物[式中、R1がn−プロピルであり、R2がn−プロピルであり、R3が水素であり、およびR4が1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イルである]:
用語「溶媒」、「不活性な有機溶媒」または「不活性な溶媒」は、それに関連して記載される反応の条件下、溶媒不活性を意味する[例えば、ベンゼン、トルエン、アセトニトリル、テトラヒドロフラン(「THF」)、ジメチルホルムアミド(「DMF」)、クロロホルム、塩化メチレン(またはジクロロメタン)、ジエチルエーテル、メタノール、ピリジンなどを含む]。特に反対がなければ、本発明の反応に用いられる溶媒は、不活性な有機溶媒であり、反応は不活性な気体、好ましくは窒素下行われる。
アルデヒド前駆体は式(2)の構造(式中R4は上記と同義)を有する市販品として入手可能ないずれかのアルデヒドであり得る。好ましいR4基は構造XY(Xはヘテロアリーレン基およびYは適宜置換されたアリールまたはアルカリール基)を有する。R4部分のこれらのタイプを含むアルデヒド前駆体は、以下の反応式5に示したように製造してもよい。
式(4)の構造を有する化合物が製造される場合、所望のR3置換を提供するように更に修飾されうる。この種の修飾は、所望のR3置換基のハライド誘導体が塩基の存在下式(4)の化合物と反応する通常の置換反応を用いて実施され得る。このような反応を行う方法は当業者によく知られており、自明である。
一般的有用性
式Iの化合物は、A2Bアデノシン受容体アンタゴニストの投与に感応する症状の治療に効果的である。かかる症状には、これらに限らないが、関節リウマチ炎、下痢、アテローム性動脈硬化症、再狭窄、糖尿病、特にII型糖尿病、黄斑変性症、糖尿病性網膜症、癌、老年痴呆症、アルツハイマー病、パーキンソン病、外傷性脳傷害、肺気腫、慢性閉塞性肺疾患、肺線維症、創傷治癒、およびI型過敏反応(喘息、アトピー性皮膚炎、および花粉症を含む)のうち少なくとも1つが含まれる。
活性試験は、上記の特許および特許出願、および以下の実施例に記載のように、および当業者に明らかな方法で行う。
式Iの化合物は通常医薬組成物の形態で投与される。従って本発明は、活性成分として、式Iの化合物、またはその医薬的に許容される塩またはエステルの1つまたはそれ以上、および医薬的に許容される賦形剤、担体(不活性な固体の希釈剤およびフィラーを含む)、希釈剤(無菌の水溶液および様々な有機溶媒を含む)、透過賦活剤(permeation enhancers)、溶解剤および補助剤の1つまたはそれ以上を含む医薬組成物を提供する。式Iの化合物は、単独または他の治療剤と組み合わせて投与され得る。かかる組成物は、医薬の技術分野でよく知られた方法で製造される[参照:例えば、Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17th Ed. (1985)および「Modern Pharmaceutics」, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes, Eds.)]。
式Iの化合物は、類似の有用性を有する薬剤投与の許容される方法、例えば、本明細書に引用される特許および特許出願に開示されているように、直腸、バッカル、鼻腔内および経皮経路、動脈内注射で、静脈内で、腹腔内で、非経口で、筋肉内で、皮下で、経口で、局所的に、吸入剤として、あるいはステントのような浸透性のまたは被膜された技巧を用いて、例えばまた、動脈に挿入されたシリンドリカルポリマーを用いる方法が含まれ、かかるいずれかの方法で、単独または多様な用量で投与され得る。
R1およびR2が同一である場合の式(1b)の化合物の製造
R1およびR2が同一である場合の式(1b)の化合物の製造
実施例1に示した手順を用いるが、ジプロピルウレアを他の二置換ウレアに換え、下記の式(1b)の化合物:
1,3,6−トリメチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジエチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(メトキシエチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ−n−ブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジイソブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(フェニルエチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジシクロブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(ピリド−4−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(フラン−3−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(4−メトキシベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(4−トリフルオロメチルベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;および
6−メチル−1,3−ジ(フルオロベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン
を製造した。
式(1c)の化合物である、6−メチル−3−プロピル−1,3−ジヒドロピリミジン−2,4−ジオンの製造
式(1c)の化合物の製造
実施例3に示した手順を用いるが、R1Hal反応剤であるヨードプロパンを他のハロゲン化誘導体に換え;下記の式(1c)の化合物:
6−メチル−3−エチル−1,3−ジヒドロピリミジン−2,4−ジオン;
3,6−ジメチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−3−メトキシ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−3−n−ブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−3−イソブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−3−フェニルエチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−3−シクロブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−3−(ピリド−4−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−3−(フラン−3−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−3−(4−メトキシベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;および
6−メチル−3−(4−フルオロベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン
を製造した。
式(1e)の化合物である、6−メチル−5−ニトロ−3−プロピル−1,3−ジヒドロピリミジン−2,4−ジオンの製造
式(1e)の化合物の製造
実施例5に示したとおりの手順を用いるが、3−プロピル−6−メチル−1,3−ジヒドロピリミジン−2,4−ジオン試薬をR1位に他の置換基を有するウラシル化合物に換え、下記の式(1e)の化合物:
6−メチル−5−ニトロ−3−エチル−1,3−ジヒドロピリミジン−2,4−ジオン;
3,6−ジメチル−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−3−メトキシ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−3−n−ブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−3−イソブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−3−フェニルエチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−3−シクロブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−3−(ピリド−4−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−3−(フラン−3−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−3−(4−メトキシベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;および
6−メチル−5−ニトロ−3−(4−フルオロベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン
を製造した。
式(1)の化合物である、6−メチル−5−ニトロ−1−エチル−3−プロピル−1,3−ジヒドロピリミジン−2,4−ジオンの製造
式(1)の化合物の製造
実施例7に示した手順を用いるが、ヨードエタン試薬を他のアルキルハライドに換え、下記の式(1)の化合物:
1,6−ジメチル−5−ニトロ−3−エチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−メトキシ−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−n−ブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−イソブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−フェニルエチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−シクロブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−(ピリド−4−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−(フラン−3−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−(4−メトキシベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−3−(4−フルオロベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−5−ニトロ−1−シクロプロピルメチル−3−エチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−1−イソブチル−3−エチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−3,6−ジメチル−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−メトキシ−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−n−ブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−イソブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−フェニルエチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−シクロブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−(ピリド−4−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−(フラン−3−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−(4−メトキシベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1−イソブチル−6−メチル−5−ニトロ−3−(4−フルオロベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−1−シクロプロピル メチル−3−エチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−3,6−ジメチル−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−メトキシ−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−n−ブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−イソブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−フェニルエチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−シクロブチル−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−(ピリド−4−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−(フラン−3−イルメチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−(4−メトキシベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン;および
1−シクロプロピル メチル−6−メチル−5−ニトロ−3−(4−フルオロベンジル)−1,3−ジヒドロピリミジン−2,4−ジオン
を製造した。
式(1)の化合物の製造
式(1)の化合物の製造
実施例9に示した手順を用いるが、6−メチル−1,3−ジプロピル−1,3−ジヒドロピリミジン−2,4−ジオンを実施例2、5および6で製造した種々の1,3−ジヒドロピリミジン−2,4−ジオン体に換え、下記の式(1)の化合物:
1,3,6−トリメチル−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−1,3−ジエチル−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−5−ニトロ−1,3−ジ(メトキシエチル)−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ−n−ブチル−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジイソブチル−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(フェニルエチル)−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジシクロブチル−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(ピリド−4−イルメチル)−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(フラン−3−イルメチル)−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(4−メトキシベンジル)−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(4−トリフルオロメチルベンジル)−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1,3−ジ(フルオロベンジル)−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
1,6−ジメチル−3−エチル−5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオン;
6−メチル−1−エチル−3−プロピル−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;
6−メチル−1−プロピル−3−メトキシエチル−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;
6−メチル−1−メトキシエチル−3−n−ブチル−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;
6−メチル−1−n−ブチル−3−イソブチル−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;
6−メチル−1−イソブチル−3−フェニルエチル−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;
6−メチル−1−フェニルエチル−3−シクロブチル−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;
6−メチル−1−シクロブチル−3−(ピリド−4−イルメチル)−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;
6−メチル−1−(ピリド−4−イルメチル)−3−(フラン−3−イルメチル)−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;
6−メチル−1−(フラン−3−イルメチル)−3−(4−メトキシベンジル)−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン;および
6−メチル−1−(4−メトキシベンジル)−3−(フルオロベンジル)−5−ニトロ−1,3−ジヒドロピリミジン2,4−ジオン
を製造した。
式(2a)の化合物の製造
式(2a)の化合物の製造
実施例11に示した手順を用いるが、ベンジルブロミドを他の適当なブロミド体に換え、下記の式(2a)の化合物:
エチル 1−メチルピラゾール−4−カルボキシレート;
エチル 1−メチルピロール−2−カルボキシレート;
エチル 1−フェニルピラゾール−4−カルボキシレート;
エチル 1−(4−メチルベンジル)ピラゾール−4−カルボキシレート;
エチル 1−(3−メトキシベンジル)ピラゾール −4−カルボキシレート;
エチル 1−(2−トリフルオロメチルベンジル)ピラゾール −4−カルボキシレート;
エチル 1−(2−フルオロベンジル)ピラゾール −4−カルボキシレート;
エチル 1−(3−トリフルオロメチルベンジル)ピラゾール −4−カルボキシレート;
エチル 1−(3−フルオロベンジル)ピラゾール −4−カルボキシレート;
エチル 1−ピリジン−4−イル−カルボキシレート;
エチル 1−ピリジン−2−イル−カルボキシレート;
エチル 1−(5−(チオフェン−2−イル)イソキサゾール−3−イル)−カルボキシレート;および
エチル 1−(N−オキシピリジン−4−イル)−カルボキシレート
を製造した。
式(2b)の化合物の製造
式(2b)の化合物の製造
実施例11に示した手順を用いるが、該カルボキシレート体を実施例10に記載したとおり製造した種々のカルボキシレート体に換え、下記の式(2b):
[1−メチルピラゾール−4−イル]メタン−1−オール;
[1−フェニルピラゾール−4−イル]メタン−1−オール;
[1−(4−メチルベンジル)ピラゾール−4−イル]メタン−1−オール;
[1−(3−メトキシベンジル)ピラゾール−4−イル]メタン−1−オール;
[1−(2−トリフルオロメチルベンジル)ピラゾール]−4−イル]メタン−1−オール;
[1−(2−フルオロベンジル)ピラゾール−4−イル]メタン−1−オール;および
[1−(4−メチルベンジル)ピラゾール−4−イル]メタン−1−オール
を製造した。
式(2)の化合物の製造
式(2)の化合物の製造
実施例15に示した手順を用いるが、該カルボキシレート体を実施例14に記載したとおり製造した種々のアルコール体に換え、下記の式(2):
[1−メチルピラゾール−4−イル]ホルムアルデヒド;
[1−フェニルピラゾール−4−イル]ホルムアルデヒド;
[1−(3−メトキシベンジル)ピラゾール−4−イル]ホルムアルデヒド;
[1−(2−トリフルオロメチルベンジル)ピラゾール]−4−イル]ホルムアルデヒド;
[1−(2−フルオロベンジル)ピラゾール−4−イル]ホルムアルデヒド;および
[1−(4−メチルベンジル)ピラゾール−4−イル]ホルムアルデヒド
を製造した。
式(3)の化合物の製造
式(3)の化合物の製造
実施例17に示した手順を用いるが、該ホルムアルデヒドを実施例15で製造した種々のホルムアルデヒド体および/またはニトロウラシル体を実施例7、8および10で製造した種々のニトロウラシル化合物に換え、下記の式(3)の化合物:
を製造した。
式(4)の化合物の製造
式(4)の化合物の製造
実施例19に示した手順を用いるが、5−ニトロ−1,3−ジヒドロピリミジン−2,4−ジオンを実施例18で製造した種々のジオン体に換え、式(4)の下記の化合物:
を製造した。
R1およびR2がプロピルであり、R3が水素であり、R4が1−メチル−1H−ピロール−2−イルである、式(I)の化合物の製造
R1およびR2がプロピルであり、R3が水素であり、R4が1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イルである、式(I)の化合物の製造
R1およびR2がプロピルであり、R3がヒドロキシであり、R4が1−ベンジル−1H−ピラゾール−4−イルである、式(I)の化合物の製造
R1およびR2がプロピルであり、R3が水素であり、R4が1−(3−フルオロベンジル)−1H−ピラゾール−4−イルである、式(I)の化合物の製造
R1およびR2がプロピルであり、R3がヒドロキシであり、R4がピリジン−4−イルである、式(I)の化合物の製造
R1およびR2がプロピルであり、R3がヒドロキシであり、R4がピリジン−2−イルである、式(I)の化合物の製造
R1およびR2がプロピルであり、R3が水素であり、R4が5−(チオフェン−2−イル)イソキサゾール−3−イルである、式(I)の化合物の製造
R1およびR2がプロピルであり、R3がヒドロキシであり、R4が1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イルである、式(I)の化合物の製造
R1およびR2がプロピルであり、R3が水素であり、R4がN−オキシピリジン−4−イルである、式(I)の化合物の製造
R1がプロピルであり、R2がエチルであり、R3が水素であり、R4が1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イルである、式(I)の化合物の製造
R1がプロピルであり、R2がメチルであり、R3が水素であり、R4が1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イルである、式(I)の化合物の製造
R1がプロピルであり、R2がシクロプロピルメチルであり、R3が水素であり、R4が1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イルである、式(I)の化合物の製造
R1がプロピルであり、R2がシクロプロピルメチルであり、R3が水素であり、R4が1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イルである、式(I)の化合物の製造
局所製剤は、下記の成分を有するように調製した:
水を除く、上記成分のすべてを併せて、60℃で攪拌しながら加熱した。次いで、60℃で充分な量の水を成分が乳濁するまで、激しく攪拌しながら加え、次いで、水を適量(100g)加えた。
徐放性組成物
本発明の徐放性製剤は、下記の通り調製される:化合物およびpH依存性結合剤ならびに任意の賦形剤のいずれかを密に混合した(乾燥混合)。次いで、乾燥混合した混合物を強塩基水溶液の存在下で顆粒化し、混合した粉末に噴霧した。該顆粒を乾燥し、ふるいにかけ、任意の滑沢剤(例えば、タルクまたはステアリン酸マグネシウム)と混合し、次いで、圧縮して錠剤とした。好ましい強塩基水溶液は、例えば、ナトリウムまたは水酸化カリウムのような水酸化アルカリ金属溶液であり、好ましくは水中(適宜、例えば、低級アルコールのような水溶性溶媒を25%まで含む)の水酸化ナトリウムがよい。
A 2B アデノシン受容体アッセイ
方法
A 2B アデノシン受容体についての放射性リガンド結合
ヒトA2Bアデノシン受容体cDNAを、HEK−293細胞(HEK−A2B細胞として言及)に安定にトランスフェクトした。HEK−A2B細胞の単層をPBS(1回)で洗浄し、10mMのHEPES(pH 7.4)、10mMのEDTAおよびプロテアーゼ阻害剤を含む緩衝液中収集した。これらの細胞を4セットで1分間ポリトロン中ホモジナイズし、15分間4℃で29000 gの遠心分離をした。細胞ペレットを10mMのHEPES(pH 7.4)、1mMのEDTAおよびプロテアーゼ阻害剤を含む緩衝液で1回洗浄し、10%ショ糖を補充した同緩衝液中再懸濁させた。凍結した分割量を−80℃に保存した。競合的アッセイは、1ユニット/mLのアデノシンデアミナーゼで補充したTE緩衝液(50mMのトリスおよび1mMのEDTA)中、10nM3H−ZM241385(Tocris Cookson)を様々な濃度の試験化合物および50μgの膜タンパク質と混合して開始した。アッセイは90分間インキュベートし、パッカード・ハーベスターを用いた濾過で止め、氷冷のTM緩衝液(10mMのトリス,1mMのMgCl2,pH 7.4)で4回洗浄した。不特定の結合は、10μMのZM241385の存在下決定した。化合物の親和性(すなわち、Ki値)はグラフパッド(GraphPad)ソフトウェアを用いて計算した。
ヒトA1、A2A、A3アデノシン受容体cDNAを、CHOまたはHEK−293細胞(CHO−A1、HEK−A2A、CHO−A3として言及)のいずれかに安定にトランスフェクトした。膜は上述のように同じプロトコールを用いてこれらの細胞から調製した。競合的アッセイは、1ユニット/mLのアデノシンデアミナーゼで補充したTE緩衝液(CHO−A1およびHEK−A2Aについて50mMのトリスおよび1mMのEDTA)またはTEM緩衝液(CHO−A3について50mMのトリス,1mMのEDTAおよび10mMのMgCl2)中、0.5nM3H−CPX(CHO−A1について)、2nM3H−ZM241385(HEK−A2A)または0.1nMの125I−AB−MECA(CHO−A3)を様々な濃度の試験化合物および該透視画法(perspective)の膜と混合して開始した。アッセイは90分間インキュベートし、パッカード・ハーベスターを用いた濾過で止め、氷冷のTM緩衝液(10mMのトリス,1mMのMgCl2,pH 7.4)で4回洗浄した。不特定の結合は、1μMのCPX(CHO−A1)、1μMのZM241385(HEK−A2A)および1μMのIB−MECA(CHO−A3)の存在下決定した。化合物の親和性(すなわち、Ki値)はグラフパッド(GraphPad)ソフトウェアを用いて計算した。
トランスフェクトされた細胞の単層は、5mMのEDTAを含むPBS中に集められた。細胞はDMEMで1回洗浄し、100,000〜500,000細胞/mlの濃度で、1ユニット/mLのアデノシンデアミナーゼを含むDMEM中再懸濁させた。100μlの細胞懸濁液を様々なアゴニストおよび/またはアンタゴニストを含む25μlと混合して、該反応液を15分間37℃に保存した。15分の終わりに、0.2N HCl(125μl)を加えて反応を終了した。細胞を10分間1000rpmで遠心分離した。上清100μlを除き、アセチル化した。上清中のAMPの濃度を、直接cAMPアッセイを用いてアッセイデザインから測定した。
A2AおよびA2Bアデノシン受容体はGsタンパク質にカップリングされる。このカップリングにより、A2Aアデノシン受容体(例えば、CGS21680)に対してのまたはA2Bアデノシン受容体(例えば、NECA)に対してのアゴニストは、cAMP蓄積を増加させる。逆に言えば、A2AおよびA2Bアデノシン受容体アンタゴニストは、アゴニストで誘発されたcAMP蓄積の増加を妨げる。
A1およびA3アデノシン受容体はGiタンパク質にカップリングされる。続いて、A1アデノシン受容体(例えば、CPA)に対してのまたはA3アデノシン受容体(例えば、IB−MECA)に対してのアゴニストは、フォルスコリンで誘発されたcAMP蓄積の増加を阻害する。A1およびA3受容体へのアンタゴニストは、cAMP蓄積における阻害を妨げる。
本発明の化合物は、上記の試験でA2B−アンタゴニストであることが示された。
Claims (32)
- R1およびR2が独立して、水素または適宜置換された低級アルキルであり;
R3が水素またはヒドロキシであり;および
R4が適宜置換された5員または6員単環式ヘテロアリール部分である、請求項1の化合物。 - R4が適宜置換された5員環ヘテロアリール部分である、請求項2の化合物。
- R4が、窒素、酸素、および硫黄からなる群から選択される少なくとも2つのヘテロ原子を含む、請求項3の化合物。
- R4が少なくとも2つの窒素ヘテロ原子を含む、請求項4の化合物。
- R4が適宜置換されたピラゾール部分である、請求項5の化合物。
- R4が適宜置換されたアルキル、適宜置換されたヘテロアリール、および適宜置換されたアリール部分からなる群から独立して選択される1から3個の置換基で置換される、請求項6の化合物。
- R4が1個のヘテロ原子だけを含む適宜置換された5員環ヘテロアリール部分である、請求項3の化合物。
- R4が、単一のOまたはSヘテロ原子を含み、適宜置換されたアルキル、適宜置換されたヘテロアリール、および適宜置換されたアリール部分からなる群から独立して選択される1から3個の置換基で置換される、請求項8の化合物。
- R4が、単一のNヘテロ原子を含み、適宜置換されたアルキル、適宜置換されたヘテロアリール、および適宜置換されたアリール部分からなる群から独立して選択される1から3個の置換基で置換される、請求項8の化合物。
- R4が適宜置換された6員環ヘテロアリール部分である、請求項2の化合物。
- R4が適宜置換されたアルキル、適宜置換されたヘテロアリール、および適宜置換されたアリール部分からなる群から独立して選択される1から3個の置換基で適宜置換されたピリジン部分である、請求項11の化合物。
- 化合物が、
8−(1−メチル−1H−ピロール−2−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−ベンジル−1H−ピラゾール−4−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−ベンジル−1H−ピラゾール−4−イル)−7−ヒドロキシ−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−(3−フルオロベンジル)−1H−ピラゾール−4−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(ピリジン−4−イル)−1,3−ジプロピル−7−ヒドロキシ−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(ピリジン−2−イル)−1,3−ジプロピル−7−ヒドロキシ−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(5−(チオフェン−2−イル)イソキサゾール−3−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;
8−(1−(3−(トリフルオロメチル)ベンジル)−1H−ピラゾール−4−イル)−7−ヒドロキシ−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオン;および
8−(N−ヒドロキシピリジン−4−イル)−1,3−ジプロピル−1H−ピロロ[3,2−d]ピリミジン−2,6−ジオンからなる群から選択される、請求項1の化合物。 - 病状が、肺疾患、糖尿病疾患、炎症性胃腸管疾患、免疫性/炎症性疾患、循環器疾患、神経疾患、および血管形成関連疾患からなる群から選択される、請求項14の治療剤。
- 病状が肺疾患である、請求項15の治療剤。
- 肺疾患が喘息である、請求項16の治療剤。
- 肺疾患が慢性閉塞性肺疾患である、請求項16の治療剤。
- 肺疾患が肺気腫である、請求項16の治療剤。
- 肺疾患が肺線維症である、請求項16の治療剤。
- 肺疾患が肺炎症である、請求項16の治療剤。
- 病状が糖尿病疾患である、請求項15の治療剤。
- 糖尿病疾患がII型糖尿病である、請求項22の治療剤。
- 病状が免疫性/炎症性疾患である、請求項15の治療剤。
- 免疫性/炎症性疾患が関節リウマチ炎である、請求項24の治療剤。
- 病状が循環器疾患である、請求項15の治療剤。
- 循環器疾患がアテローム性動脈硬化症である、請求項26の治療剤。
- 病状が炎症性胃腸管疾患である、請求項15の治療剤。
- 炎症性胃腸管疾患が下痢である、請求項28の治療剤。
- 病状が神経疾患である、請求項15の治療剤。
- 神経疾患が老年痴呆症、アルツハイマー病、またはパーキンソン病である、請求項30の治療剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51601903P | 2003-10-31 | 2003-10-31 | |
US60/516,019 | 2003-10-31 | ||
PCT/US2004/035453 WO2005042534A2 (en) | 2003-10-31 | 2004-10-26 | A2b adenosine receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007509947A JP2007509947A (ja) | 2007-04-19 |
JP2007509947A5 JP2007509947A5 (ja) | 2007-11-15 |
JP4863876B2 true JP4863876B2 (ja) | 2012-01-25 |
Family
ID=34549473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006538172A Active JP4863876B2 (ja) | 2003-10-31 | 2004-10-26 | A2bアデノシン受容体アンタゴニスト |
Country Status (13)
Country | Link |
---|---|
US (1) | US7449473B2 (ja) |
EP (1) | EP1678181B1 (ja) |
JP (1) | JP4863876B2 (ja) |
KR (1) | KR20060111467A (ja) |
CN (1) | CN1890241A (ja) |
AT (1) | ATE419252T1 (ja) |
AU (1) | AU2004285013A1 (ja) |
BR (1) | BRPI0415888A (ja) |
CA (1) | CA2544193C (ja) |
DE (1) | DE602004018808D1 (ja) |
ES (1) | ES2318363T3 (ja) |
MX (1) | MXPA06004789A (ja) |
WO (1) | WO2005042534A2 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
RU2385322C2 (ru) * | 2004-09-01 | 2010-03-27 | Си Ви Терапьютикс, Инк. | Способ заживления ран с применением антагонистов аденозинового рецептора a2b |
EP1799221A1 (en) | 2004-10-15 | 2007-06-27 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
CN101198608B (zh) * | 2005-06-16 | 2011-04-27 | 吉利德帕洛阿尔托股份有限公司 | A2b腺苷受体拮抗剂的前药 |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
JP2009528389A (ja) * | 2006-03-02 | 2009-08-06 | シーブイ・セラピューティクス・インコーポレイテッド | A2aアデノシン受容体拮抗剤 |
CN101460501A (zh) * | 2006-06-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 作为髓过氧化物酶抑制剂的吡咯并[3,2-d]嘧啶-4-酮衍生物 |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
US7470697B2 (en) * | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
GB0718432D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
GB0718434D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
TW200938200A (en) * | 2007-12-28 | 2009-09-16 | Dainippon Sumitomo Pharma Co | Methyl-substituted piperidine derivative |
JP5460690B2 (ja) | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
US20110118276A1 (en) * | 2008-07-16 | 2011-05-19 | Edward Leung | Methods of treating atherosclerosis |
DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
WO2010103547A2 (en) | 2009-03-13 | 2010-09-16 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
EP2571882A1 (en) * | 2010-05-21 | 2013-03-27 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
AU2011303420B2 (en) | 2010-09-13 | 2014-03-20 | Impetis Biosciences Ltd. | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications |
JP6132853B2 (ja) * | 2011-12-27 | 2017-05-24 | アラーガン、インコーポレイテッドAllergan,Incorporated | 全身性抗炎症反応を提供する、複数のプロスタグランジン受容体で作用する化合物 |
WO2015003881A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000694A1 (en) * | 2001-06-22 | 2003-01-03 | Almirall Prodesfarma S.A. | 6-phenyldihydropyrrolopyrimidinedione derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1254915B (it) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
DE19535504A1 (de) | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
WO2001094350A1 (en) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
WO2003006465A1 (en) * | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
AU2002359365B2 (en) | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
-
2004
- 2004-10-26 AU AU2004285013A patent/AU2004285013A1/en not_active Abandoned
- 2004-10-26 DE DE602004018808T patent/DE602004018808D1/de active Active
- 2004-10-26 CN CNA200480031969XA patent/CN1890241A/zh active Pending
- 2004-10-26 AT AT04810023T patent/ATE419252T1/de not_active IP Right Cessation
- 2004-10-26 CA CA2544193A patent/CA2544193C/en active Active
- 2004-10-26 WO PCT/US2004/035453 patent/WO2005042534A2/en active Application Filing
- 2004-10-26 KR KR1020067008426A patent/KR20060111467A/ko not_active Application Discontinuation
- 2004-10-26 US US10/973,167 patent/US7449473B2/en active Active
- 2004-10-26 MX MXPA06004789A patent/MXPA06004789A/es unknown
- 2004-10-26 JP JP2006538172A patent/JP4863876B2/ja active Active
- 2004-10-26 ES ES04810023T patent/ES2318363T3/es active Active
- 2004-10-26 BR BRPI0415888-1A patent/BRPI0415888A/pt not_active Application Discontinuation
- 2004-10-26 EP EP04810023A patent/EP1678181B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000694A1 (en) * | 2001-06-22 | 2003-01-03 | Almirall Prodesfarma S.A. | 6-phenyldihydropyrrolopyrimidinedione derivatives |
Also Published As
Publication number | Publication date |
---|---|
DE602004018808D1 (de) | 2009-02-12 |
WO2005042534A3 (en) | 2005-08-25 |
MXPA06004789A (es) | 2006-07-03 |
ES2318363T3 (es) | 2009-05-01 |
WO2005042534A2 (en) | 2005-05-12 |
BRPI0415888A (pt) | 2007-01-09 |
KR20060111467A (ko) | 2006-10-27 |
ATE419252T1 (de) | 2009-01-15 |
EP1678181B1 (en) | 2008-12-31 |
JP2007509947A (ja) | 2007-04-19 |
CA2544193C (en) | 2012-03-27 |
CN1890241A (zh) | 2007-01-03 |
CA2544193A1 (en) | 2005-05-12 |
US20050119287A1 (en) | 2005-06-02 |
EP1678181A2 (en) | 2006-07-12 |
US7449473B2 (en) | 2008-11-11 |
AU2004285013A1 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4863876B2 (ja) | A2bアデノシン受容体アンタゴニスト | |
JP4350517B2 (ja) | A2bアデノシン受容体アンタゴニスト | |
US8324224B2 (en) | A2B adenosine receptor antagonists | |
JP5044823B2 (ja) | A2bアデノシンレセプターアンタゴニストのプロドラッグ | |
US7521554B2 (en) | A2B adenosine receptor antagonists | |
US6977300B2 (en) | A2B adenosine receptor antagonists | |
AU2002359365A1 (en) | A2B adenosine receptor antagonists | |
US7304070B2 (en) | A2B adenosine receptor antagonists | |
EP1622908B1 (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
Kalla et al. | Substituted pyrrolo [3, 2-d] pyrimidin-2, 4-diones as A 2b adenosine receptor antagonists | |
RU2318825C2 (ru) | Производные ксантина в качестве антагонистов a2b аденозинового рецептора | |
KR20060055453A (ko) | A2b 아데노신 수용체 길항제로서의 크산틴 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070925 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070925 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111025 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111108 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141118 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4863876 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |